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7Abstract 
Adolescence is often characterized by delayed and irregular sleep patterns, with 
potential negative consequences in terms of school performance and daytime 
functioning. At the most extreme, a stably delayed sleep phase may reflect a circadian 
rhythm sleep disorder of the delayed sleep phase type (delayed sleep phase disorder, 
DSPD). DSPD is assumed to be common amongst adolescents and young adults, but 
little is known about its prevalence and aetiology, and no guidelines exist with respect 
to treatment. 
 The aims of the theses were 1) to address the prevalence and correlates of a 
delayed sleep phase (DSP) in a large and representative sample of Norwegian high 
school students, 2) to investigate objective measures of sleep, circadian rhythm and 
phase angle relationship between the underlying circadian rhythm and sleep timing in 
adolescents and young adults with DSPD when allowed to sleep on a self-chosen 
schedule and 3) to investigate short- and long-term effects on sleep of bright light and 
melatonin administered alongside gradual advancement of rise time in adolescents 
and young adults with DSPD. The aims were addressed using two different study 
designs.  
 Study 1 was an internet-based, cross sectional survey conducted on 1285 
Norwegian high school students. The survey included items on background, 
demography, sleep and daytime functioning and the validated questionnaires the 
Hospital Anxiety and Depression Scale (HADS) and the Alcohol Use Disorder 
Identification Test (AUDIT). DSP was operationalized as difficulties falling asleep 
before 2 a.m. at least 3 nights per week together with much/very much difficulties 
awakening in the morning. The results showed a prevalence of DSP of 8.4% (paper 
1). Students with DSP slept less during weekdays and had more often weekend 
rebound sleep than students without DSP. DSP was associated with negative 
outcomes in terms of poorer school grades, more smoking, more use of alcohol and 
increased symptoms of anxiety and depression.  
8 Study 2 combined a case control study and a clinical trial in a comprehensive 
design into which 40 adolescents and young adults with DSPD and 21 healthy 
controls were recruited to participate. In the case control study, sleep on a self-chosen 
schedule was assessed in patients with DSPD and controls by means of 
polysomnography (PSG). Circadian rhythm was assessed by measuring salivary dim 
light melatonin onset (DLMO). Results showed delayed timing of sleep and delayed 
DLMO in the patients with DSPD compared to the healthy controls (paper 2). Sleep, 
however, appeared to occur at a similar phase angle, and once sleep was initiated no 
differences in sleep duration or sleep architecture were observed between the groups. 
In the clinical trial, the DSPD patients were randomized to receive treatment for two 
weeks in one of 4 treatment conditions: dim light and placebo capsules, bright light 
and placebo capsules, dim light and melatonin capsules and bright light and melatonin 
capsules. In a follow-up study, participants were re-randomized to either receive 
treatment with the combination of bright light and melatonin or no treatment in an 
open label trial for approximately three months. Light and melatonin were always 
administered alongside gradual advancement of rise times. Sleep was assessed by 
sleep diaries, actigraphy recordings, the Pittsburgh Sleep Quality Index (PSQI) and 
the Bergen Insomnia Scale (BIS). Circadian rhythm was assessed by measuring 
DLMO. Results showed that the timing of sleep and DLMO were advanced in all 
groups after short-term treatment, with no additional effect of bright light and 
melatonin (paper 3). Termination of treatment produced a relapse to baseline levels 
whereas continued treatment using bright light and melatonin together with adjunct 
behavioural instructions allowed maintenance of the sleep rhythm. 
 In conclusion, we found in study 1 a high prevalence of DSP in our sample of 
Norwegian high school students (paper 1). DSP was associated with lower school 
grades, more smoking, more alcohol use and higher scores on anxiety and depression. 
In study 2 we found that patients with DSPD had delayed timing of sleep and DLMO, 
whereas sleep architecture and phase angle relationship appeared to be normal when 
patients were allowed to sleep according to a self-chosen sleep schedule (paper 2). 
Short-term treatment of patients with DSPD involving bright light and melatonin 
9alongside gradual advancement of rise time produced a phase advance irrespective of 
treatment condition (paper 3). Long-term treatment with bright light and melatonin 
alongside gradual advancement of rise time allowed maintenance of the sleep rhythm 
whereas termination of treatment caused relapse into delayed sleep times.  
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Sammendrag på norsk 
Ungdom har ofte et forsinket og uregelmessig søvnmønster, med potensielt negative 
effekter på skoleprestasjoner og dagtidsfungering. I ekstreme tilfeller kan et stabilt 
forsinket søvnmønster reflektere døgnrytmeforstyrrelsen forsinket søvnfasesyndom 
(delayed sleep phase disorder, DSPD). Pasienter med DSPD har 
innsovningsproblemer og problemer med å våkne til ønsket tid om morgenen, og de 
kan derfor ha store vansker med å tilpasse seg samfunnsrytmen. Kunnskapen vi har 
om utbredelse og etiologi av DSPD er imidlertid mangelfull, og det eksisterer i dag 
ingen retningslinjer for behandling.
 Målsetningene for denne avhandling var derfor 1) å estimere forekomst og 
korrelater til forsinket søvnfase (delayed sleep phase, DSP) i et representativt utvalg 
av elever ved norske videregående skoler, 2) å sammenligne objektive mål på søvn, 
døgnrytme og fasevinkelen mellom den endogene døgnrytmen og søvnperioden hos 
ungdom og unge voksne med DSPD og friske kontroller når de selv valgte tidspunkt 
for søvn og 3) å undersøke kort- og langtidseffekter på søvn av behandling med lys og 
melatonin sammen med instruksjoner om å stå opp gradvis tidligere hos ungdom og 
unge voksne med DSPD. Disse målsetningene ble adressert gjennom to studiedesign.
 Studie 1 var en tverrsnittstudie gjennomført blant 1285 elever i norsk 
videregående skole. Elevene besvarte et internettbasert spørreskjema med spørsmål 
relatert til bakgrunn, demografi, søvn og dagtidsfungering, i tillegg til validerte 
spørreskjema på symptomer på angst og depresjon (Hospital Anxiety and Depression 
Scale, HADS) og bruk av alkohol (Alcohol Use and Disuse Identification Test, 
AUDIT). DSP ble operasjonalisert som vansker med å sovne før klokken 02:00 minst 
3 netter per uke sammen med store/svært store vansker med å våkne om morgenen. 
Resultatene viste en forekomst av DSP på 8,4 % (artikkel 1). Studenter med DSP sov 
mindre på ukedager og tok oftere igjen søvn i helgene enn studenter uten DSP. DSP 
var assosiert med negative utfall i form av dårligere skolekarakterer, mer røyking, mer 
bruk av alkohol og økte symptomer på angst og depresjon.
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 Studie 2 kombinerte en sammenlikningsstudie og en klinisk studie i et helhetlig 
forsøksdesign. Tilsammen 40 ungdommer og unge voksne med DSPD og 21 friske 
kontroller ble rekruttert til å delta. I sammenlikningsstudien undersøkte vi 
polysomnografiske (PSG) mål på søvn hos pasienter med DSPD og kontroller når de 
selv fikk velge tidspunkt for søvn. Vi estimerte døgnrytme ved å finne tidspunkt for 
økt melatoninkonsentrasjon i spytt ved fravær av lys (dim light melatonin onset, 
DLMO). Resultatene viste at tidspunktet for søvn og DLMO var forsinket hos 
pasienter med DSPD (artikkel 2). Imidlertid fant søvnperioden hos deltakere i begge 
grupper sted på samme fasevinkel, og etter innsovning observerte vi ingen forskjeller 
mellom gruppene med tanke på søvnlengde og søvnarkitektur. I den kliniske studien 
ble DSPD-pasientene randomisert til behandling i to uker i en av fire 
behandlingsbetingelser: svakt lys og placebo kapsler, sterkt lys og placebo kapsler, 
svakt lys og melatonin kapsler og sterkt lys og melatonin kapsler. I en 
oppfølgingsstudie ble deltakerne re-randomisert til enten å få behandling med 
kombinasjonen sterkt lys og melatonin eller ingen behandling i 3 måneder. Lys og 
melatonin ble alltid kombinert med instrukser om å stå opp gradvis tidligere. Søvn ble 
målt ved hjelp av søvndagbøker, aktigrafer og de validerte spørreskjemaene 
Pittsburgh Sleep Quality Index (PSQI) og Bergen Insomnia Scale (BIS). Døgnrytmen 
ble estimert ved å måle DLMO. Resultatene viste at tidspunkt for søvn og DLMO ble 
framskyndet i alle grupper under korttidsbehandling, uten at sterkt lys og melatonin 
ga forsterket effekt (artikkel 3). Avsluttet behandling ga et tilbakefall til forsinket 
søvnmønster etter tre måneder, mens fortsatt behandling med lys og melatonin 
opprettholdt et fremskyndet søvnmønster. 
 Oppsummert, fant vi en høy forekomst av DSP hos elever i norsk videregående 
skole (artikkel 1). DSP var assosiert med dårligere skolekarakterer, mer røyking, mer 
alkoholbruk og økte symptomer på angst og depresjon. Pasienter med DSPD hadde 
forsinket tidspunkt for søvn og DLMO, men søvnarkitektur og fasevinkel syntes å 
være normal når pasientene selv fikk velge tidspunkt for søvn (artikkel 2). 
Korttidsbehandling av pasienter med DSPD med lys og melatonin og instrukser om å 
stå opp gradvis tidligere fremskyndet tidspunktet for søvn og DLMO uavhengig av 
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behandlingsbetingelse. Langtidsbehandling av DSPD med lys og melatonin 
opprettholdt et framskyndet søvnmønster mens avslutning av behandling forårsaket 
tilbakefall til forsinket søvnmønster. 
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1. INTRODUCTION 
All animal species alternate between periods of activity and rest, in accordance with 
fluctuations of the surrounding environment such as variations in access to food, 
ambient temperature and daylight. Biological rhythms that are aligned with the 24 
hour light/dark cycle are referred to as circadian, from the Latin circa diem 
(approximately one day). The circadian oscillations are innate to the organisms and 
are present also in temporal isolation, although usually slightly longer than 24 hours 
(Aschoff, 1965; Czeisler et al., 1999). These rhythms entrain to match the length of a 
day through external cues (zeitgebers) of which daylight is believed to be the most 
important (Czeisler et al., 1989). Circadian rhythms may promote adaptive behaviour, 
for example by ensuring inactivity when access to food is low and/or predator risk is 
high. Some animals are active during the dark phase (nocturnal) whereas others, like 
humans, are mostly active during the light phase of the day (diurnal). The inactivity 
phase is usually accompanied by sleep, defined as a reversible behavioural state of 
perceptual disengagement from and unresponsiveness to the environment (Carskadon 
and Dement, 2011).  
 Circadian rhythm sleep disorders are characterized by a misalignment between 
the internal sleep/wake cycle and the surrounding environment (World Health 
Organization, 1992; American Psychiatric Association, 2000; American Academy of 
Sleep Medicine, 2005) and result in complaints of insomnia, excessive daytime 
sleepiness or both (American Academy of Sleep Medicine, 2005). Whereas secondary 
circadian rhythm sleep disorders are inflicted by external factors such as traveling 
across time zones (jet lag type) or shift work (shift work type), less is known about 
the aetiology of primary types (e.g. delayed and advanced sleep phase disorders) 
(American Academy of Sleep Medicine, 2005). In the delayed sleep phase disorder 
(DSPD) the timing of the sleep period is delayed in relation to normal or desired sleep 
times. DSPD has potentially large impact on the lives of afflicted individuals, still 
little is known about DSPD in terms of prevalence, pathophysiology and treatment. 
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The present thesis aims to address some of these aspects, hopefully contributing to 
increased understanding and ultimately to better clinical management of patients with 
DSPD. 
1.1 Sleep  
Sleep in mammals is characterized by two distinct stages, rapid eye movement (REM) 
sleep and non-rapid eye movement (NREM) sleep. These sleep stages can be 
identified by polysomnography (PSG) recordings which involves electrophysiological 
recordings of brain activity (electroencephalogram, EEG), eye movements 
(electrooculogram, EOG) and muscular activity (electromyogram, EMG) 
(Rechtschaffen and Kales, 1968; Iber et al., 2007; Carskadon and Dement, 2011). 
Wakefulness is defined by high frequency (beta range, >17 Hz), low voltage 
oscillations in the EEG. The NREM stages N1, N2 and N3 are characterized by 
progressively slower EEG activity. Background activity during the stages N1 and N2 
is in the theta frequency range (5-7 Hz) whereas N3 is defined by the presence of high 
amplitude EEG waves in the low delta frequency range (<2 Hz) (Iber et al., 2007; 
Carskadon and Dement, 2011). Accordingly, stage N3 is often referred to as slow 
wave sleep (SWS) or delta sleep. Due to a high wake up threshold in N3, the term 
deep sleep is sometimes used. In contrast, REM sleep displays high frequency, low 
amplitude EEG together with rapid eye movements and muscular atonia (Iber et al., 
2007; Carskadon and Dement, 2011). REM sleep normally constitutes approximately 
20-25% of the sleep period, whereas 5%, 50% and 20-25% are spent in the NREM 
stages N1, N2 and N3, respectively (Carskadon and Dement, 2011). The sleep stages 
are temporally organized within the major sleep period into 4-6 NREM-REM cycles 
of approximately 90 minutes each. N3 is abundant during the first sleep cycles of the 
sleep period, REM sleep during the latter (Carskadon and Dement, 2011) .  
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Sleep regulation 
According to the two-process model for sleep regulation, sleep is regulated in an 
interplay between circadian and homeostatic processes (Borbely, 1982). The circadian 
factor promotes sleep during certain periods of the day, to a large degree determining 
the duration of the sleep period (Czeisler et al., 1980; Dijk and Czeisler, 1995) 
(Fig.1). The homeostatic factor represents a sleep propensity that accumulates during 
time spent awake and is reflected by the amount and intensity of N3 (Borbely et al., 
1981; Banks and Dinges, 2007). Extended periods of wakefulness are followed by 
increased amounts of N3, and after sleep deprivation the rebound of deep sleep occurs 
at the cost of other sleep stages. Deep sleep is believed to be crucial in order to feel 
awake and alert. In humans, habits and behaviour may override and influence the 
biological drives (e.g. voluntary wake during the normal sleep period, drinking coffee, 
etc.) (Carskadon et al., 2004; Bjorvatn and Pallesen, 2009). 
Figure 1. Sleep duration is controlled by the interplay between the homeostatic factor 
(H) and the circadian factor (C). H builds up during wakefulness (W) and is released 
during sleep (S). Wake up occurs when the H curve crosses the C curve. Habits and 
behaviour determine the time for sleep onset (T) (Ursin, 2008). 
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1.2 Circadian rhythms 
Circadian rhythms are seen not only as oscillations in behaviour (sleep/wake, 
activity/inactivity), but also as daily variations in physiological processes such as 
hormone secretion (e.g. melatonin, cortisol), body temperature, renal activity and gene 
transcription (Kryger et al., 2011). Peripheral organs and cells in vitro display 
circadian rhythmicity in the absence of external cues, with period lengths (Ĳ) ranging 
from 20 – 30 hours (Gachon et al., 2004; Yoo et al., 2004). These circadian 
oscillations are of genetic origin, and rely on transcriptional feedback loops involving 
the clock genes Clock, Bmal1, Per1, Per2, Cry1 and Cry 2, recently reviewed by 
Mohawk et al. (2012). 
Circadian regulation 
The mechanisms through which the peripheral circadian rhythms are synchronized 
and aligned with the 24 hour light/dark cycle are known to mainly rely on the action 
of a central pacemaker, the suprachiasmatic nucleus (SCN) (Kryger et al., 2011; 
Mohawk et al., 2012). SCN resides in the hypothalamus just above the optic chiasma. 
The Ĳ of the SCN is normally slightly longer than 24 hours (Aschoff, 1965; Czeisler et 
al., 1999; Herman, 2011) but entrains to the length of a day through external stimuli 
(zeitgebers). Light appears to be the most important zeitgeber in humans (Czeisler et 
al., 1989; Duffy et al., 1996), and works by activating retinal cells such as the 
melanopsin expressing photoreceptive ganglion cells which project directly to the 
SCN through the retino-hypothalamic tract (Do and Yau, 2010). The SCN coordinates 
the peripheral rhythms through effects on hormone secretion and body temperature, in 
addition to more complex pathways and feedback loops involving autonomic control 
and local signals (Gachon et al., 2004; Mohawk et al., 2012). Through indirect 
neuronal pathways, the SCN regulates the pineal secretion of melatonin (Pandi-
Perumal et al., 2008). Melatonin is suppressed by light and released in the dark, and is 
involved in the regulation of several physiological processes with a reciprocal 
influence on the circadian phase of the SCN. 
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Measuring circadian rhythms 
The phase, length (Ĳ) and amplitude of the endogenous period can be identified by 
measuring circadian oscillations in physiological processes, often core body 
temperature or melatonin secretion, under conditions that minimize the influences of 
external temporal cues (unmasking). Unmasking is often done by imposing days of 
abnormal length, outside the range of entrainment by the internal clock (forced 
desynchrony) or by using a constant routine protocol (Mills et al., 1978; Minors and 
Waterhouse, 1984; Brown and Czeisler, 1992). In a constant routine protocol, 
unmasking is achieved by keeping potential temporal cues such as sleep/wake, 
lightning, heating, humidity, posture, activity, mealtimes etc. constant over 24 hours 
or more (Minors and Waterhouse, 1984). On a constant routine protocol the core body 
temperature, usually measured using a rectal temperature probe, is higher during the 
subjective day and declines in the evening to reach a minimum (core body 
temperature minimum, CTmin) about 2 hours before spontaneous/habitual wake up 
time (Bjorvatn and Pallesen, 2009). Melatonin (N-acetyl-5-methoxytryptamine) is 
measured in saliva or plasma, or through its metabolite 6-sulphatoxymelatonin in 
urine (Benloucif et al., 2008). Melatonin levels during the day are low, but increase in 
the evening in the absence of light, about 7 hours before CTmin (Brown et al., 1997), 
to reach an acrophase in the middle of the sleep period. The time of CTmin and the 
time at which melatonin secretion increase in the evening in the absence of light (dim 
light melatonin onset, DLMO) are considered reliable markers of circadian phase 
(Lewy et al., 1985; Herman, 2011). In recent years, partial protocols for salivary 
DLMO assessment have been validated, allowing at home based assessment of 
circadian phase (Pandi-Perumal et al., 2007; Pullman et al., 2012). 
Entrainment by light 
Although behaviour and other non-photic zeitgebers (e.g. sleep/wake cycle, activity 
levels, food intake, ambient temperature) may contribute to entrainment, it has been 
established that light is the most important zeitgeber in humans (Czeisler et al., 1989; 
Duffy et al., 1996). Its effects (direction and size) largely depend on the time of 
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exposure, as described by the phase response curves (PRC) for light (Minors et al., 
1991; Khalsa et al., 2003) (Fig.2). Morning bright light, shortly after the core body 
temperature minimum (CTmin), produces a phase advance whereas light prior to 
CTmin produces a phase delay (Minors et al., 1991; Khalsa et al., 2003; Bjorvatn and 
Pallesen, 2009). Light in close proximity to CTmin produces a larger phase 
advance/delay, and in a non-linear manner, light with higher intensity (measured in 
lux) has a stronger phase shifting capacity (Zeitzer et al., 2000).  
 When administered at adequate times, intensities and durations, bright light can 
be used to manipulate the circadian rhythm, for example in the treatment of circadian 
rhythm sleep disorders or affective disorders with associated circadian dysregulation 
(Wirz-Justice, 2003). In clinical practice, patients may be advised to ensure exposure 
to outdoor light at optimal times. Light therapy lamps for indoor use are also 
commercially available and may be a good alternative, in particular at high or low 
latitudes during the dark season. Normally, these lamps emit high intensity light (5000 
– 10 000 lux) in the visible part of the spectrum (380-760 nm). Using full spectrum 
light with 10 000 lux intensity, common exposure time is 30 minutes (Terman and 
Terman, 2011). The side-effects of bright light therapy are usually minor and of short-
term duration (Wyatt, 2004). A line of research has indicated that the SCN may be 
particularly sensitive to high energy light (short wavelength light, blue spectrum ~480 
nm) (Wright and Lack, 2001; Lockley et al., 2003), and lamps emitting blue enriched 
lights are also available for purchase. However, PRC’s for lights of the different 
wavelengths (Revell et al., 2012; Ruger et al., 2013) as well as safety of use should be 
established before clinical application can be recommended.  
Entrainment by melatonin 
Chronobiotics are agents with the ability to shift the endogenous circadian phase 
(Dawson and Armstrong, 1996). Melatonin is a potent chronobiotic that has been 
extensively studied, likely exerting its effects through its reciprocal interaction with 
the SCN (Pandi-Perumal et al., 2008). The PRC for melatonin is about 12 hours out 
of phase with light (Lewy et al., 1992; Lewy et al., 1998) (Fig.2).  
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 In clinical practice exogenous melatonin (0.3-5 mg) may be administered in the 
evening to achieve a phase advance (Fuardiola-Lemaître and Quera-Salva, 2011). The 
phase delaying effects of melatonin administered in the morning have been more 
questioned (Wirz-Justice et al., 2002; Fuardiola-Lemaître and Quera-Salva, 2011). 
When melatonin and light therapy are employed together, melatonin may be 
administered about 12 hours prior to bright light exposure (Bjorvatn and Pallesen, 
2009). No classical dose response relationship for exogenous melatonin has been 
found, but different doses appear to have different time windows for optimal effects 
(PRCs), probably due to wash-over effects (Burgess et al., 2010). There has been 
some controversy regarding use of melatonin in children and adolescents since there 
is little knowledge of teratogenicity, interaction effects, long-term effects and effects 
on the reproductive system of melatonin (Arendt, 1997).  
Figure 2. Phase response curves for light (thick black line) and melatonin (thin grey 
line) based on studies by Khalsa et al. (2003) and Lewy et al. (1998). Light/melatonin 
at times when the curves are above the dotted line will produce a phase advance, 
when curves are below the dotted line they produce a phase delay. Nadir is the core 
body temperature minimum (CTmin).
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Diurnal preference 
Some people feel more alert and prepared for mental and physical activity during the 
early part of the day, others in the later. Such diurnal preference is closely connected 
to the sleep/wake pattern, and evening types (night owls) tend to go to bed and rise at 
later times than morning types (morning larks) and they often have more irregular 
sleep schedules (Giannotti et al., 2002). The diurnal preference is believed to be an 
innate trait reflecting differences in the underlying circadian phase, possibly related to 
different alleles of several clock genes (yielding chronotypes along a continuum from 
morningness to eveningness) (Katzenberg et al., 1998). Eveningness appears to be a 
risk factor for poor mental and physical health (Randler, 2011), as well as low school 
attendance, reduced school performance, risk-taking and bad health behaviour (e.g., 
use of tobacco and alcohol as well as inadequate dietary habits, see Cavallera et al.
(2011) for review). 
1.3 Sleep in adolescents 
Adolescence is often characterized by irregular weekday/weekend sleep patterns as 
recently reviewed by Gradisar et al. (2011b), as well as increased daytime sleepiness 
and increased evening preference (Carskadon et al., 1980; Carskadon et al., 1993; 
Crowley et al., 2007). Late bed times together with early imposed rise times due to 
school obligations produce sleep curtailment during weekdays. In contrast, sleep 
duration during weekends is often prolonged, in part due to rebound or recovery 
sleep, and the late bed times are accompanied by late rise times. However, sleeping in 
on weekends may further contribute to the sleep/wake rhythm delay, making it 
difficult to fall asleep at appropriate times on following evenings. By this, some 
adolescents conceive themselves trapped in a vicious cycle/positive feedback loop. 
 A biological basis for the adolescent sleep phase delay is suggested by the facts 
that it is not confined to western cultures or even the human species (Hagenauer et al., 
2009), and that it appears to correlate with pubertal development rather than age 
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(Carskadon et al., 1993). According to sleep regulatory principles (Borbely, 1982) 
alterations in the timing of sleep may originate from homeostatic or circadian 
alterations, and there is evidence that both are involved in the adolescent sleep phase 
delay as reviewed by Hagenauer et al. (2009). Still, adolescence is accompanied by 
reduced parental control, and the 24 hour society (services open and available around 
the clock), television, computers, internet, cellular phones and increased norm 
pressure from peers produce great enticements for being awake at night (Ferrara and 
De Gennaro, 2001), potentially causing a delay of sleep onset.  
 The adolescent sleep phase delay may have severe consequences. Rising at 
times when the biological clocks are set for sleep, adolescents with a delayed sleep 
phase may experience problems performing optimally during school hours due to the 
circadian fluctuations in subjective sleepiness, cognition, attention and physical 
performance (Carrier and Monk, 2000). Moreover, the need for sleep does not decline 
during puberty (Carskadon et al., 1980), and since school normally starts early in the 
morning many adolescents are forced to rise before they have received adequate 
sleep. Chronic sleep curtailment causes sleepiness and may have widespread 
implications on both physiological and neurobehavioral functioning (Banks and 
Dinges, 2007; Akerstedt et al., 2012), the neurobiological effects of sleep debt 
accumulating over time (Van Dongen et al., 2003). In line with this, several studies 
have showed an association between poor sleep habits and reduced academic 
performance in adolescents (Wolfson and Carskadon, 1998; Wolfson and Carskadon, 
2003; Dewald et al., 2010). Poor sleep habits also appear to be linked to overweight, 
depressive mood, smoking and alcohol usage (Carskadon et al., 1998; Meijer et al., 
2010; Owens et al., 2010; Pallesen et al., 2010; Pasch et al., 2010; Garaulet et al., 
2011). Oversleeping is another common consequence of a delayed sleep phase, 
affecting school attendance and consequently contributing to poor school 
performance.  
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1.4 Delayed sleep phase disorder  
Circadian rhythm sleep disorders are characterised by a misalignment between the 
sleep/wake rhythm and the external environment (American Academy of Sleep 
Medicine, 2005). Delayed sleep phase disorder (DSPD, previously termed delayed 
sleep phase syndrome, DSPS) (American Academy of Sleep Medicine, 1990; 
American Academy of Sleep Medicine, 2005) was first described by Weitzman et al.
(1981) as a chronobiological disorder with sleep onset insomnia. In the second edition 
of the International Classification of Sleep Disorders (ICSD-2), DSPD is defined as 
“a delay in the phase of the major sleep period in relation to the desired sleep time 
and wake-up time, as evidenced by a chronic or recurrent complaint of inability to 
fall asleep at a desired conventional clock time together with the inability to awaken 
at a desired and socially acceptable time” (American Academy of Sleep Medicine, 
2005). According to the ICSD-2, sleep quality and duration are normal when patients 
are allowed to sleep on a self-preferred sleep schedule, and sleep diary or actigraphy 
for at least a week show a delayed but stable habitual sleep period (American 
Academy of Sleep Medicine, 2005).  
1.4.1 Prevalence  
DSPD is assumed to be the most frequent circadian rhythm sleep disorder (Dagan and 
Eisenstein, 1999), but few studies have been published addressing the prevalence of 
DSPD as diagnosed according to ICSD-2 (American Academy of Sleep Medicine, 
2005) (Table 1). A large Norwegian study yielded a prevalence of 0.17% (Schrader et 
al., 1993) in an adult sample whereas a prevalence rate of 0.14% was reported from a 
corresponding Japanese study (Yazaki et al., 1999). Although the prevalence in 
adolescent samples is believed to be higher, 7-16% according to the ICSD-2 
(American Academy of Sleep Medicine, 2005), only data from survey studies are 
available. Without the use of sleep logs to confirm the diagnosis it is difficult to 
differentiate between DSPD, eveningness and a normal adolescent sleep phase delay, 
and different sets of criteria have been used to identify DSPD-like symptoms. 
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Accordingly, results from survey studies have been ambiguous, ranging from 0.48 to 
almost 17 % (Table 1). Nevertheless, it appears that at least a mild form of DSPD/a 
severe sleep phase delay/extreme eveningness is common amongst adolescents and 
young adults, potentially causing problems for the youngsters.  
Table 1. Prevalence studies of delayed sleep phase disorder/a severe sleep phase delay 
Publication N Age Methods Prevalence (%) 
(Yazaki et al., 1999) 1525 15-59 Confirmed diagnosis 0.13 
(Schrader et al., 1993) 9918 18-67 Confirmed diagnosis 0.17 
(Hazama et al., 2008) 4971 Students Survey 0.48 
(Ohayon et al., 2000) 3294 15-24 Telephone interview <0.5 CRSD2
(Ando et al., 1995) 1 417 40-64 Survey 0.7 
(LeBlanc et al., 1999) 1 1743 12-20 Confirmed diagnosis 1.3 
(Pelayo et al., 1988) 1 109 12-19 Survey 7.3 
(Brown et al., 2001) 191 17-55 
(average 19) 
Survey 11.5 
(Lack, 1986) 211 16-50 
(average 23) 
Survey 16.6 
1Abstract, 2Circadian rhythm sleep disorder 
1.4.2 Correlates and comorbidity 
Patients with DSPD experience challenges commonly associated with delayed and 
irregular sleep patterns in terms of school adherence and daytime functioning 
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(Crowley et al., 2007). DSPD has also been shown to have high comorbidity with 
other conditions such as depression (Thorpy et al., 1988; Regestein and Monk, 1995; 
Regestein and Pavlova, 1995), learning disabilities (Dagan and Eisenstein, 1999) and 
personality disorders (Dagan et al., 1998a).  
1.4.3 Aetiology  
Although genetic markers related to DSPD have been described (Archer et al., 2003; 
Hohjoh et al., 2003) the pathophysiology of DSPD is still largely unknown (American 
Academy of Sleep Medicine, 2005). The sleep phase delay is assumed to reflect an 
underlying delay in the endogenous rhythm, and accordingly several studies have 
shown delayed measures of circadian rhythms in terms of DLMO (Shibui et al., 1999; 
Wyatt et al., 2006; Chang et al., 2009) and CTmin (Watanabe et al., 2003; Chang et 
al., 2009) in patients with DSPD. Czeisler et al. (1981) suggested that patients with 
DSPD have long Ĳ, making it hard for them to adequately entrain to the light/dark 
cycle. Campbell and Murphy (2007) recorded Ĳ in a patient with DSPD in temporal 
isolation. This patient had an average Ĳ of 25.38 hours, compared to 24.44 in the 
healthy controls. Reduced phase advancing capacity may also be caused by 
abnormalities in light sensitivity, and it has been suggested that patients with DSPD 
have reduced sensitivity to light. In contrast, one study has found a more pronounced 
suppression of nocturnal melatonin secretion by light in these patients (Aoki et al., 
2001). Thus, it is possible that patients suffering from DSPD are hypersensitive to 
light, allowing evening light to cause a phase delay. Another source of 
pathophysiology is suggested by several reports of longer phase angle relationships 
(time interval) between measures of circadian rhythmicity and sleep in patients with 
DSPD (Ozaki et al., 1996; Uchiyama et al., 2000a; Uchiyama et al., 2000b; Watanabe
et al., 2003; Campbell and Murphy, 2007). The prolonged phase angle in patients 
with DSPD may be explained by the finding by Uchiyama et al. (1999) of reduced 
sleep propensity in patients with DSPD after sleep deprivation, indicating that 
homeostatic processes may play a role in DSPD either in terms of reduced 
accumulation of homeostatic factor during wakefulness or reduced ability to release 
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the homeostatic factor when allowed to sleep. A longer phase angle may promote 
sleep during a larger part of the most potent phase advance period, thus impairing the 
ability to phase adjust. Research is, however, not univocal, and neither Wyatt et al.
(2006) nor Chang et al. (2009) found differences in phase angles, whereas Shibui et 
al. (1999) found a prolonged phase angle relationship between melatonin and sleep 
offset but not sleep onset, a result that may be explained by longer total sleep time. It 
appears that the correlation between DLMO and sleep onset is lower in patients with 
DSPD than in healthy individuals (Keijzer et al., 2011). Adding further complexity, 
evening types have been found to actually have shorter phase angle than morning 
types (Baehr et al., 2000; Liu et al., 2005). It has been debated whether patients with 
DSPD display extreme eveningness or if the two conditions are caused by different 
aetiologies. Mongrain et al. (2004) have suggested that evening types often follow an 
enforced rhythm, hence shortening the phase angle whereas patients with DSPD more 
often sleep according to their internal rhythm, the late sleep offset producing a longer 
phase angle relationship. Hence, the inconsistencies in phase angle can be explained 
in terms of external constraints acting differentially on individuals along the 
morningness – eveningness continuum. It is, however, possible that the two 
conditions are caused by qualitatively different aetiologies. According to the view of 
Dagan and Eisenstein (1999), DSPD reflects a distinct clinical entity characterized by 
rigidity in the circadian rhythm. Also social factors and habits are likely to play 
important roles in the aetiology of DSPS. Bad habits such as staying up late and 
sleeping in will phase delay the circadian rhythm, and a vulnerable subject may enter 
a vicious circle facilitating development of the syndrome (Whyte and Schaefer, 1995).  
1.4.4 Sleep 
Since DSPD is commonly believed to rely on abnormalities in the circadian regulation 
system, sleep quality and duration have been assumed to be normal when patients are 
allowed to sleep on a self-preferred sleep schedule (American Academy of Sleep 
Medicine, 2005). It is possible, however, that other sleep regulatory mechanisms 
responsible for the sleep phase delay may influence duration and/or architecture of 
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sleep. Disturbances in homeostatic processes may affect amount and distribution of 
SWS. Furthermore, sleeping at a later endogenous time (longer phase angle) may 
have implications for both sleep duration and architecture (Dijk, 1999). The only 
controlled study where polysomnographic measures of sleep were reported for 
patients with DSPD (Watanabe et al., 2003) on non-imposed sleep schedules revealed 
prolonged sleep onset latency, more wake after sleep onset, reduced sleep efficiency 
and reduced SWS. The reduced sleep quality was attributed by the authors to a longer 
phase angle in which sleep offset was delayed in relation to the core body temperature 
nadir (Watanabe et al., 2003).   
1.4.5 Treatment 
The most common treatment approaches for DSPD are based on behavioural 
interventions, administration of bright light and/or exogenous melatonin or 
combinations of these (Barion and Zee, 2007; Morgenthaler et al., 2007; Bjorvatn and 
Pallesen, 2009). The use of hypnotics is generally not an option in these patients, 
since effective treatment should aim to correct the underlying circadian delay. 
Although much is known about the chronobiological effects of light and melatonin, 
no standardized guidelines exist regarding treatment for DSPD, and treatment is often 
available only at specialized sleep clinics.  
Bright light therapy 
The use of bright light exposure in treatment of DSPD was first suggested by Lewy et 
al. (1985), but its effect has been assessed in few controlled studies (Rosenthal et al., 
1990; Cole et al., 2002; Lack et al., 2007; Gradisar et al., 2011a). In a cross-over 
study by Rosenthal et al. (1990), CTmin was advanced with almost one and a half 
hour in patients with DSPD when receiving 2500 lux for two hours in the morning 
over two weeks but not in the dim light condition. Similarly, Lack et al. (2007) 
reported a two and a half hour advance of DLMO in DSPD patients receiving 
morning blue light for one week with no phase advance in the dim light control group. 
Restriction of evening light facilitates sleep phase advancement (Rosenthal et al., 
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1990; Cole et al., 2002). Hence, in line with current evidence and chronobiological 
principles, light after CTmin should produce an advance of the endogenous circadian 
rhythm in patients with DSPD.  
Behavioural interventions 
The first treatment proposed for DSPD was chronotherapy; a gradual delay of the 
sleep period (usually 3 hours per day) until the desired timing of sleep was achieved 
(Czeisler et al., 1981). This treatment regime was based on the assumption that 
patients with DSPD had reduced capacity to phase advance, and in the original report 
(Czeisler et al., 1981) chronotherapy successfully shifted the timing of sleep in 5 
patients who also were able to maintain the newly achieved sleep phase over longer 
periods by adhering to strict stable sleep schedules. Chronotherapy is, however, time 
consuming, and several cases of hypernyctohermal syndrome/free running disorder 
(American Academy of Sleep Medicine, 2005), have been reported after 
chronotherapy (Oren and Wehr, 1992). Hence, chronoterapy is generally not a 
recommended treatment for DSPD. 
 Bright light is usually administered together with behavioural instructions such 
as gradual advancement of rise time (Cole et al., 2002; Lack et al., 2007; Gradisar et 
al., 2011a) or fixed advanced sleep/wake schedules (Sharkey et al., 2011). 
Interestingly, some of these studies have shown phase advancement also in dim light 
control groups (Cole et al., 2002; Sharkey et al., 2011). In the study by Sharkey et al.
(2011), participants with “subclinical DSPD” advanced DLMO with approximately 
one and a half hour in both a blue light and a dim light condition by adherence to 
fixed advanced sleep/wake schedules. Hence, it appears that sleep schedules may act 
as a determinant for circadian phase in patients with DSPD. It is, however, possible 
that behavioural instructions are sufficient to produce a phase advance only in the 
patients with less severe phase delay. Accordingly, Cole et al. (2002), reported 
superior effects of the bright light condition only in the participants whose initial 
circadian delay was most severe. Behavioural interventions addressing possible 
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associated conditioned sleep onset insomnia have also been suggested as part of 
DSPD treatment protocols (Lack and Wright, 2007; Gradisar et al., 2011a). 
Exogenous melatonin 
Few controlled studies have addressed the effect of melatonin in treatment of DSPD 
(Dahlitz et al., 1991; Nagtegaal et al., 1998b; Kayumov et al., 2001; Mundey et al., 
2005; Rahman et al., 2010a). Kayumov et al. (2001) and Rahman et al. (2010a) both 
reported reduced sleep onset latency (SOL) on an early imposed sleep schedule after 
treatment with melatonin. In a study by Nagtegaal et al. (1998b), melatonin advanced 
DLMO with one and a half hour whereas CTmin remained unchanged. The authors 
speculated whether the results could be attributed to the soporific rather than 
chronobiotic actions of melatonin. In contrast, Mundey et al. (2005) found that 
melatonin advanced both DLMO and CTmin with about one and a half hour, but that 
sleep onset and offset remained unchanged. In a study by Dahlitz et al. (1991) sleep 
onset was advanced compared to the placebo group, but not compared to pre-
treatment levels. Based on these findings and results from studies on children and 
adolescents with sleep onset difficulties (Smits et al., 2001; Smits et al., 2003; Weiss
et al., 2006; Van der Heijden et al., 2007), a recent meta-analysis concluded that 
melatonin effectively produce a phase advance in patients with DSPD (van Geijlswijk
et al., 2010).
Timing for administration of treatment 
Appropriate timing for administration of bright light/melatonin in DSPD can be 
ensured by measuring DLMO or CTmin (Nagtegaal et al., 1998b; Lockley, 2005; 
Mundey et al., 2005). When such biological markers of circadian phase are not 
available, DLMO and CTmin can be estimated from behaviour and anamnestic 
information, based on the facts that DLMO usually occurs approximately two hours 
before habitual sleep onset (Revell et al., 2006) and CTmin approximately two hours 
before habitual wake up time (Bjorvatn and Pallesen, 2009). Still, individual timing of 
treatment may not be superior to fixed times as shown by Nagtegaal et al. (1998b). In 
32
previous treatment studies, melatonin has often been administered at approximately 
the same time throughout the treatment period (Dahlitz et al., 1991; Nagtegaal et al., 
1998b; Kayumov et al., 2001; Mundey et al., 2005; Rahman et al., 2010a), despite the 
fact that a shift in circadian phase will cause a parallel phase shift of the phase-
response curve for melatonin (Lewy et al., 1998). Gradual advancement of time for 
bright light/melatonin administration alongside gradual advancement of the sleep 
schedule has proved effective in advancing the circadian phase in healthy populations 
(Burgess et al., 2003; Revell et al., 2006), and several researchers have suggested 
DSPD treatment protocols based on this principle (Cole et al., 2002; Revell et al., 
2006; Lack et al., 2007; Bjorvatn and Pallesen, 2009; Gradisar et al., 2011a).
Long-term treatment 
Little is known about long-term treatment of DSPD. Several clinical reports indicate 
that the effect of light and melatonin fades out upon termination of treatment (Alvarez
et al., 1992; Dagan et al., 1998b; van Maanen et al., 2011). Accordingly, treatment 
protocols should address the sleep phase delay in a two-step manner by 1) achieving 
and 2) maintaining a phase advance. Cole et al. (2002) reported maintenance of 
advanced sleep onset times after four weeks in a bright light condition when 
compared to baseline but not compared to the dim light control group. Maintenance 
treatment by light therapy 2-4 days per week may be useful for some patients (Wyatt, 
2004). It is, however, possible that some patients are able to maintain an advanced 
sleep phase through strict sleep schedules. In line with this, Gradisar et al. (2011a) 
showed that DSPD-patients were able to maintain treatment effects for six months by 
adhering to a behavioural regime following initial short-term treatment with bright 
light and cognitive behavioural therapy. In a study by Czeisler et al. (1981), patients 
were able to maintain an advanced sleep schedule after chronotherapy (follow-up 
between 6 weeks and 2.5 years).  
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Treatment in children and adolescents 
Treating children and adolescents with DSPD involves special challenges when 
compared to adult populations, both in terms of physiology and behaviour. In 
particular, motivational issues may have a strong impact on compliance to treatment, 
since most treatment protocols involve structuring the daily schedule. Hence, it seems 
important to address treatment effectiveness within a particular age group. Few 
controlled studies have, however, addressed treatment of children and young adults 
with DSPD. To our knowledge, the study by Gradisar et al. (2011a) in which a phase 
advance was produced through cognitive behavioural therapy in combination with 
morning bright light, is the only previous controlled treatment study conducted on 
adolescents diagnosed with DSPD. The use of melatonin in children and adolescents 
with sleep onset difficulties (possibly due to a delayed sleep phase) has been more 
extensively investigated and appears to advance sleep onset and DLMO, and possibly 
also increase sleep duration (Smits et al., 2001; Smits et al., 2003; Weiss et al., 2006; 
Van der Heijden et al., 2007; Eckerberg et al., 2012). 
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2. Research aims  
The main aims of this thesis were 1) to investigate prevalence and correlates of 
delayed sleep phase (DSP) in a representative adolescent sample, 2) to compare 
objective measures of sleep and circadian phase in patients with delayed sleep phase 
disorder (DSPD) to that of healthy controls, and 3) to address short- and long-term 
treatment effects on sleep of bright light and melatonin in patients with DSPD in a 
randomized controlled design. These aims were addressed in three papers:
Paper 1 
The aims of paper 1 were to estimate the prevalence of DSP, operationalized as 
difficulties falling asleep before 2 a.m. at least 3 nights per week together with 
much/very much difficulties awakening in the morning, in a large sample of 
Norwegian high school students, and to identify correlates of DSP in terms of 
smoking, alcohol use, body mass index (BMI), school grades, and anxiety and 
depression scores. 
Paper 2 
The aims of paper 2 were to investigate polysomnographic measures of sleep in 
adolescents and young adults with DSPD on a self-chosen sleep schedule compared to 
healthy controls, and to estimate circadian phase (DLMO) and its phase angle in 
relation to the sleep period.  
Paper 3 
The first aim of paper 3 was to investigate and compare short-term treatment effects 
of bright light and melatonin when administered alongside gradual advancement of 
rise times in patients with DSPD in a randomized, four-armed, double blinded, 
placebo controlled design. The second aim was to investigate long-term treatment 
effects of bright light and melatonin in combination in a randomized, two-armed 
follow-up design. Main end points were subjective and objective measures of sleep as 
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recorded by one week of sleep diary and actigraphy prior to treatment, the last week 
of the two-week intervention and the last week of the three-month follow-up, as well 
as measures of circadian phase (DLMO) before and after the two-week intervention. 
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3. METHODS 
Publications from two different studies are included in the theses. Paper 1 is based on 
a cross sectional survey conducted amongst high school students in Hordaland 
County, Norway (Study 1). Papers 2 and 3 are based on a combined case control 
study/clinical trial (ClinicalTrials.gov NCT00834886) conducted on adolescents and 
young adults in Bergen, Norway (Study 2).  
3.1 Study 1 
3.1.1 Sample 
The sample consisted of 1285 high school students (610 girls and 669 boys, 6 
unanswered) from 115 school classes in Hordaland County, Norway. The students 
were between 16 and 19 years, with a mean age of 17.3 years (SD = 0.9). 
3.1.2 Procedure 
The study was conducted in collaboration with the central Regional School 
Administration of Western Norway during spring 2004, and participation was 
incorporated into the school day activities. The survey was internet based and students 
participated by logging anonymously onto a given internet address where they 
responded to a questionnaire composed of items on demography, gambling, alcohol 
use/abuse, drug use/abuse, and anxiety and depression. Paper 1 presents data from 
items relating to sleep and daytime functioning, demography as well as validated 
questionnaires on alcohol use/abuse and anxiety and depression. Other results from 
the survey are not part of this thesis. 
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3.1.3 Instruments 
Demography 
The items covering demography and background information were age, gender, 
weight, height, smoking (yes/no) and self-reported average school grade (scale from 
1, lowest to 6, highest).  
Sleep questions 
A total of 15 items about sleep and sleep habits were included in the questionnaire, of 
which 11 were included in the present paper. Five of these items were particularly 
relevant, as they were used to operationalize delayed sleep phase (DSP) and to 
identify the students with DSP who also reported related daytime impairment and 
problems advancing the sleep phase: 
o How many days per week do you have difficulties falling asleep before 2 a.m.? 
(0-7) 
o On average, how many days per week are you late for school, work or 
appointments due to oversleeping? (0-7) 
o Do you usually feel sleepy at school or work during weekdays? (not at all, a 
little, moderate, much, very much) 
o Do you have difficulties waking up in the morning on weekdays? (not at all, a 
little, moderate, much, very much) 
o Would it be easy for you to go to bed earlier, fall asleep earlier and wake up 
earlier in the morning than what you now usually do on weekdays? (not at all, 
a little, moderate, much, very much) 
We operationalized delayed sleep phase (DSP) as difficulties falling asleep before 2 
a.m. at least 3 nights per week together with much or very much difficulties waking 
up in the morning. DSP together with much or very much problems advancing the 
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sleep phase and at least one daytime consequence was also assessed. A daytime 
consequence was defined as oversleeping at least two days per week and/or reporting 
much or very much sleepiness at school. 
 The remaining six items concerned bed time, sleep onset latency (SOL) and 
wake up time on weekdays and weekends, respectively. Time in bed (TIB) was 
defined as the time interval from bed time to wake up time. Total sleep time (TST) 
was defined as TIB minus SOL. Students with TST weekend minus TST weekday > 
120 minutes were considered to have weekend rebound sleep.   
Alcohol Use Disorders Identification Test (AUDIT)  
AUDIT is a self-report instrument measuring use and potentially misuse of alcohol 
(Saunders et al., 1993). It consists of ten items; the first eight are rated on a 5 point 
scale (0-4), whereas the two last items are rated on a 3 point scale (0-2-4). Higher 
scores are associated with higher levels of drinking problems. A score above 10 
suggests harmful drinking. Cronbach’s alpha for AUDIT was 0.84 in the present 
study. 
The Hospital Anxiety and Depression Scale (HADS)  
HADS is a self-report instrument measuring symptoms of anxiety and depression 
(Zigmond and Snaith, 1983). It consists of two subscales with 7 items each, assessing 
non-vegetative symptoms of anxiety and depression, respectively. Each item is rated 
on a four point scale (0-3). Higher scores are associated with higher symptom levels. 
A score of 8 or more on each scale suggests possible cases of anxiety/depression. 
Chronbach’s alpha for the anxiety and depression subscales were 0.69 and 0.64, 
respectively.  
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3.1.4 Ethics 
The study was anonymous and a passive consent procedure was applied. The study 
was approved by the Regional Ethics Committee of Western Norway (REK-West) 
and Norwegian Social Data Service (NSD). 
3.2 Study 2 
3.2.1 Sample 
Adolescents and young adults with DSPD and healthy controls were recruited from 
high schools, colleges and the University of Bergen between 2008 and 2011. A total 
of 264 potential DSPD participants and 55 healthy controls volunteered for 
participation. They were screened through a short telephone interview and one week 
of sleep diary. Altogether 60 potential DSPD participants and 31 healthy controls 
fulfilled the basic criteria for inclusion and were scheduled for a meeting at the sleep 
laboratory (Faculty of Psychology, University of Bergen). A total of 10 potential 
DSPD participants and 7 healthy controls withdrew prior to or during this meeting, at 
which the potential participants were screened with SCID-I (First et al., 1995), 
Raven’s matrices (Raven, 2000; Raven et al., 2000) and a pregnancy test (females), 
and further set up for a polysomnographic screening. A total of 40 participants with 
DSPD and 21 healthy controls were included for participation in the study. Paper 2 
includes data from the 54 participants with valid polysomnography recordings, 35 
with DSPD and 19 healthy controls. Paper 3 includes all the 40 participants enrolled 
to participate in the treatment study (ClinicalTrials.gov NCT00834886). Fig.3 
illustrates participation flow of the study. 
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Figure 3. Participant flow of study 2 
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Inclusion and exclusion criteria 
Inclusion criteria for the study were 1) living in Bergen, Norway, 2) age 16-25 years, 
3) good general health as specified by the exclusion criteria and 4) DSPD diagnosis 
OR fulfilling the criteria for healthy controls. DSPD was diagnosed according to the 
diagnostic criteria of the ICSD-2 (American Academy of Sleep Medicine, 2005), 
operationalized as 1) problems falling asleep in the evening, 2) falling asleep after 2 
a.m. at least 3 days a week, 3) ability to sleep until early afternoon, 4) problems 
waking up in time for school/studies, 5) early wake-up times associated with extreme 
daytime sleepiness, 6) good subjective sleep quality and duration when given the 
opportunity to sleep at preferred times and 7) reporting the abovementioned sleep 
problems for more than 6 months. The diagnosis was confirmed by one week of sleep 
diary showing sleep onset later than 2 a.m. at least 3 days per week. Criteria for 
healthy controls were responding “no” to item 1 through 5, confirmed by one week of 
sleep diary showing sleep onset before midnight at least three days per week, later 
than 2 a.m. no more than 2 days per week, and sleep onset latency > 30 minutes less 
than 3 days per week. 
 Exclusion criteria were sleep disorders other than DSPD based on subjective 
reports and polysomnography (apnea-hypopnea index > 5 and periodic limb 
movement index > 15), moderate to severe psychopathology or treatment for 
psychopathology within the last 4 weeks (based on SCID-I interviews), somatic 
disorders or conditions assumed to affect sleep (i.e. migraine, B12 deficiency), all 
serious somatic disorders (i.e. rheumatoid arthritis, diabetes), medications assumed to 
affect sleep (i.e. sedative anti-histamines, antidepressants, hypnotics), substance 
abuse, night work, IQ < 70 (Raven’s matrices), breast feeding and pregnancy. 
3.2.2 Procedure 
Study design 
The study was partly at home based and partly laboratory based. The first part of the 
study (baseline assessment) was identical for all participants (DSPD and controls). 
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The study schedule is illustrated in Fig.4. Participants in both groups kept a sleep 
diary and wore an actigraph for 7 days prior to intervention. Subsequently, 
participants slept according to a self-chosen sleep schedule for 4 consecutive 
nights/days. On nights 3 and 4, participants underwent PSG. On night 5, saliva 
samples for estimation of DLMO were collected. On day 5 participants were to rise at 
7 a.m. for daytime testing in the sleep laboratory (8 a.m. – 3 p.m.). In the sleep 
laboratory, participants were tested on different aspects of daytime functioning and 
completed several questionnaires including the Pittsburgh Sleep Quality Index (PSQI) 
and the Bergen Insomnia Scale (BIS). The controls had by this completed the study, 
whereas participants with DSPD entered the clinical trial.  
In the clinical trial, starting on day 6, the DSPD participants were randomized 
into one of 4 treatment conditions each lasting for 2 weeks in a double blinded, 
placebo controlled design. The 4 treatment conditions were: dim light and placebo 
capsules (placebo group), bright light and placebo capsules (bright light group), dim 
light and melatonin capsules (melatonin group) and bright light and melatonin 
capsules (combination group). In the follow-up study, participants were re-
randomized into one of 2 groups to receive treatment with the combination of bright 
light and melatonin (treatment group) or no treatment (no-treatment group) in an open 
label trial for approximately 3 months. The participants kept a sleep diary and wore an 
actigraph during the last 7 days of the two-week intervention (two-week assessment) 
and during the last 7 days of the three-month follow-up study (three-month 
assessment). At the end of the intervention periods, saliva samples were collected for 
estimation of DLMO (not reported for three-month assessment due to small sample 
size), and on the subsequent day participants came to the sleep laboratory for daytime 
testing. Capsules were not administered on the evening prior to DLMO assessment. 
Compliance, possible side effects and adverse events were logged. 
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Figure 4. Study schedule of study 2 
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Paper 2 presents results from the case control study with respect to the 
polysomnographic measures of sleep from night 4 and DLMO estimates from night 5. 
Paper 3 presents results from the clinical trial at all three assessment points in terms 
of sleep (sleep diary, actigraphy, PISQI and BIS). DLMO estimates from the first two 
assessment points are also presented in this paper. Other results from the study are not 
part of the thesis. 
Treatment protocol 
Dim/bright light and placebo/melatonin capsules were administered together with 
adjunct behavioural instructions. Participants were instructed to sleep until 
spontaneous awakening on the first day of treatment (if they woke much earlier than 
their habitual wake up time they were to stay in bed and try to go back to sleep). Rise 
time was then to be advanced with one hour each day until preferred rise time was 
achieved (as chosen by the individual participant). This preferred rise time was to be 
maintained throughout the treatment period. Light was administered every day 
immediately upon awakening, for 30 – 45 minutes, with eyes directed towards the 
lamp and in a distance providing approximately 10 000 lux. In the evenings, 12 hours 
after awakening, participants were to take a capsule. However, for safety reasons 
related to the soporific properties of melatonin, capsules were not to be taken before 8 
p.m. In the case of oversleeping, participants were to take light immediately upon 
awakening, melatonin 12 hours later and to advance rise time with one hour on the 
following days. No information was given regarding bed time. Use of alcohol was not 
allowed during the 2 week intervention. No restrictions for alcohol use were given for 
the 3 month follow-up study.  
Bright light and dim light 
The light source was ML-10 000 (47 x 17.5 x 29 cm) from Miljølys Inc., Norway. In 
the two-week intervention, lamplight was either bright (approximately 10 000 lux on 
50 cm distance) containing three fluorescent bulbs (Philips, Ecotone, P1-L, RA-
index=80, light temperature 4000 K) with a transparent cover screen or dim 
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(approximately 400 lux on 50 cm distance, placebo) with 1 fluorescent bulb and a 
dark red cover screen. In the three-month intervention, all participants received bright 
light. 
Melatonin capsules and placebo capsules 
The melatonin (5-methoxy-N-acetyltryptamine) 3 mg was purchased from Nature’s 
One, Asman Inc, USA. For the two-week intervention, hard capsules containing 
either melatonin 3 mg or 3 mg of Maydis Amylum (maize starch, placebo) were 
packed by Kragerø Tablettproduksjon Inc., Norway. For the 3 month follow-up study, 
the original capsules from Nature’s One were used. 
Blinding 
The 2 week intervention was double blinded. Lamps were packed in boxes concealing 
the colour of the cover screen and sealed by two PhD students at the Faculty of 
Psychology, University of Bergen, Norway. Participants received information that 
light could be either white or red, but not that light intensity was different or that the 
red light was regarded a placebo condition. To ensure double blinding, participants 
were thoroughly instructed not to reveal the colour of the lamp to the study personnel 
upon return. Capsules were packed and blinded by Kragerø Tablettproduksjon Inc., 
Norway. The codes were not broken until all data were collected and analysed. The 3 
month follow-up study was not blinded.   
Randomization 
Prior to study start, two randomization lists were produced (4 groups x two-week 
intervention, 2 groups x three-month follow-up), using the internet based program 
Research Randomizer (http://www.randomizer.org.form.htm). Upon enrolment 
participants were chronologically assigned to the respective groups according to these 
lists. 
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3.2.3 Instruments 
Polysomnography (PSG) 
Electrodes were montaged and recordings analysed according to ‘The AASM Manual 
for the Scoring of Sleep and Associated Events’ (Iber et al., 2007). Embla Titanium® 
recorder and the Somnologica™ Studio 5.1 (Embla Systems Inc., USA) were used for 
data acquisition and analysis. All PSG recordings were ambulatory. Participants were 
prepared with electrodes in the sleep laboratory at a self-chosen time between 6 p.m. 
and 10 p.m. to suit their daily routines. They then retired to their homes to sleep in 
their own beds. Two nights of PSG were performed (nights 3 and 4). The first night 
was regarded as an adaptation night to account for confounding first night effects and 
also served as a screening night for sleep apnea and periodic limb movement disorder. 
On the second night, sensors for respiratory events were omitted to minimize 
discomfort for the participants. Only data from the second night were used in the 
analyses. A description of sleep parameters included in analyses can be found in paper 
2.   
Actigraphy 
Actiwatch recorder was used for data acquisition and Actigraphy Sleep Analysis 
software for data analyses (Cambridge Neurotechnology Ltd, England). Data were 
collected with an epoch length of 1 minute. Sensitivity was set to medium. A 
description of sleep parameters included in analyses can be found in paper 3. 
Sleep diary 
The sleep diary items included bed time and rise time, sleep onset latency (SOL), 
number and length of awakenings, wake up time and sleep quality (scale from 1=very 
light to 5=very deep). A description of sleep parameters included in analyses can be 
found in paper 3. 
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Pittsburgh Sleep Quality Index (PSQI) 
The Pittsburgh Sleep Quality Index is a 19 item, self-rated questionnaire which 
assesses sleep quality and disturbances over a 1-month time interval (Buysse et al., 
1989). Global score range from 0 – 21, higher scores indicating more sleep problems. 
The cut off for problematic sleep is set to 5.  
Bergen Insomnia Scale (BIS) 
BIS is a 6 item self-report instrument, constructed based upon current formal and 
clinical diagnostic criteria for insomnia (Pallesen et al., 2008). Each item is rated 
along an 8-point scale, ranging from 0 to 7 days per week, yielding a total score 
ranging from 0 to 42.  
Dim light melatonin onset (DLMO) 
Saliva was collected using Salivette® tubes from Sarstedt, Germany and analyzed 
with enzyme-linked immunosorbent assay (ELISA) from Bühlmann laboratories, 
Switzerland. Analytical sensitivity of this kit is 0.5 pg/ml and functional sensitivity is 
1.6-20.5 pg/ml with an inter-assay coefficient of variation of less than 30%. Samples 
were analyzed with Wallac plate reader from Perkin Elmer Inc., USA. The melatonin 
sampling procedure was based on the protocol for a partial melatonin curve as 
advised by Pandi-Perumal et al. (2007), but with modifications due to logistic reasons 
related to the design of the study. Participants were instructed to stay at home on the 
evening of the DLMO assessment (night 5). Saliva was sampled hourly from 7 p.m. 
and until self-chosen bed time. One hour prior to sampling start (6 p.m.) participants 
put on dark sunglasses (Uvex athletic ISO 9001, Uvex winter holding, Germany) 
reducing light intensity to less than 1% (for example 690 lux was reduced to 5.6 lux). 
During the collection period participants were instructed to avoid drinks with artificial 
colorants, alcohol or caffeine, and to avoid tooth brushing, lipstick/lip gloss, chewing 
gum, lemons and bananas. Participants were instructed not to eat, drink or use tobacco 
for the last 30 minutes before sampling. Samples were labelled, kept in the 
refrigerator and brought to the sleep laboratory the next morning. In the sleep 
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laboratory, samples were kept in a -22ºC freezer before they were transported to the 
immunoassay laboratory where they were stored in a -80ºC freezer until time of 
analysis.  
 DLMO was calculated by interpolation between the last sample before and the 
first sample after the saliva concentration reached 4 pg/ml, or extrapolation from the 
last 2 values when concentration reached 3, but not 4 pg/ml (Keijzer et al., 2011). The 
calculations were done based on the scheduled sampling times (7 p.m., 8 p.m., etc). 
Phase angle relationship was calculated as the time interval from DLMO to sleep 
onset and from DLMO to sleep offset (times for sleep onset and offset were derived 
from the PSG recording on night 4).  
3.2.4 Ethics 
The study was conducted according to Good Clinical Practice (GCP), and the PhD-
students conducting the trial were GCP certified. Internal monitoring procedures were 
incorporated in the design. Participants received written and oral information about 
the study before consent forms were signed. When participants were < 18 years, 
written and verbal consent from both the adolescent and the parents were obtained. 
Participants received a compensation fee (approximately 60 EURO for participants 
with DSPD, approximately 25 EURO for healthy controls) for the time invested. The 
study was approved by the Regional Committee for Medical and Health Research 
Ethics, the Norwegian Social Data Service and the Norwegian Medicines Agency. 
The clinical trial was registered at ClinicalTrials.gov with registration number 
NCT00834886. 
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3.3 Statistics 
Paper 1 
Means were compared between subjects with DSP and subjects without DSP using t-
tests for independent samples. Frequencies were compared using Pearson chi-square 
test with continuity correction for 2 x 2 tables. Logistic regression analyses were 
conducted using DSP/not DSP as dependent variable and age, gender, smoking, 
alcohol use, BMI, self-reported average school grade, anxiety score and depression 
score as independent variables. The variables were entered both separately (crude 
logistic regression analysis) and simultaneously (adjusted logistic regression analysis). 
Paper 2 
Means for the different sleep parameters, DLMO and phase angle were compared 
between participants in the DSPD group and the control group using t-tests for 
independent samples. Effect sizes (Cohen’s d = M1-M2/SD pooled) were calculated 
using an online calculator: http://easycalculation.com/statistics/effect-size.php. 
Paper 3 
In cases of drop outs/missing data, values were moved forward from the baseline 
assessment (intention to treat). Due to the smaller sample, intention to treat was not 
used for DLMO analyses. Background and demographic variables were compared 
between groups using one-way ANOVA, t-tests for independent samples and Pearson 
chi square tests. Intervention effects were compared between the groups using two-
way ANOVA for repeated measures (baseline vs. two-week assessment, baseline vs. 
three-month assessment, two-week assessment vs. three-month assessment). 
Interaction effects were further assessed using t-tests for paired samples within each 
group. Cohen’s d was calculated using the formula d=M1-M2/(sqrt(SD12+SD22)/2). 
50
4. SUMMARY OF RESULTS 
Paper 1 
A sample of 1285 high school students (aged 16-19 years) participated in an internet 
based study answering questions about sleep habits, height, weight, smoking, alcohol 
use, school grades, and anxiety and depression symptoms. Delayed sleep phase (DSP) 
was operationalized as difficulties falling asleep before 2 a.m. at least 3 nights per 
week together with much or very much difficulties waking up in the morning. The 
prevalence of students reporting DSP in the present study was 8.4%. The students 
with DSP had shorter TST during weekdays due to later bed times and longer sleep 
onset latencies whereas TST during weekends did not differ from students without 
DSP. Students with DSP more frequently reported weekend rebound sleep (76% 
compared to 52 % in students without DSP). Logistic regression analyses showed that 
average school grade was negatively whereas smoking, alcohol use and scores on 
anxiety and depression were positively associated with DSP. DSP was not associated 
with age, gender or BMI. Students with DSP who also reported daytime consequences 
and problems advancing the sleep period constituted 5.7% of the total sample (68% of 
all students reporting DSP). In conclusion, DSP appeared to be common amongst 
Norwegian adolescents and was associated with negative outcomes such as lower 
average school grades, smoking, alcohol usage and elevated anxiety and depression 
scores.  
Paper 2 
Polysomnographic data from 54 adolescents and young adults (age range 16-25 years) 
sleeping on a self-chosen schedule were analysed, 35 diagnosed with DSPD and 19 
healthy controls. Salivary dim light melatonin onset (DLMO) was measured on the 
evening following the PSG recording. Results showed delayed timing of sleep in 
participants with DSPD in terms of bed time (2:32 ± 124 min compared to 23:50 ± 69 
min in the control group, p<.0005) and rise time (12:55 ± 113 min compared to 09:01 
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± 70 min in the control group, p<.0005). Participants with DSPD had longer sleep 
onset latency, but once sleep was initiated no group differences in sleep parameters 
were observed with respect to sleep duration or architecture, as illustrated by two 
representative hypnograms in Fig.5. DLMO was delayed with more than 3 hours in 
participants with DSPD, but no difference in phase angle was observed between the 
groups. In conclusion, both sleep and DLMO were delayed in participants with 
DSPD. The sleep period appeared to occur at a similar phase angle in both groups, 
and once sleep was initiated no differences in sleep parameters were observed. 
Figure 5. Two representative hypnograms showing the sleep stage distribution in a 
healthy control (top) and a participant with DSPD (bottom). Differences were only 
related to the timing of sleep. 
Paper 3 
A total of 40 adolescents and young adults (age range 16-25 years) diagnosed with 
DSPD were randomized to receive two weeks of treatment in one of four treatment 
conditions: dim light and placebo capsules, bright light and placebo capsules, dim 
light and melatonin capsules, bright light and melatonin capsules. Subsequently, 
participants were re-randomized into one of two groups to receive treatment for three 
months (bright light and melatonin) or no treatment. Light and capsules were 
administered alongside gradual advancement of rise times. Main end points were 
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subjective and objective measures of sleep as recorded by sleep diary and actigraphy, 
and estimation of DLMO (at baseline- and two-week assessment). Self-reported sleep 
problems was addressed using the Pittsburgh Sleep Quality Index (PSQI) and the 
Bergen Insomnia Scale (BIS). At two-week assessment the timing of sleep and 
DLMO were advanced in all four treatment conditions as seen by about 1 hour 
advance of bed time, 2 hours advance of rise time and 2 hours advance of DLMO in 
all groups. TST was reduced with approximately 1 hour. Scores on the PSQI and the 
BIS improved across the groups. At three-month follow-up, only the treatment group 
had maintained an advanced sleep phase whereas the no-treatment group had relapsed 
to baseline levels. TST had returned to baseline levels in both groups. Scores on the 
PSQI were further improved in the treatment group but not in the no-treatment group. 
In conclusion, gradual advancement of rise time produced a phase advance during the 
two-week intervention, irrespective of treatment condition. Termination of treatment 
caused relapse into delayed sleep times, whereas long-term treatment with bright light 
and melatonin (three months) allowed maintenance of the sleep rhythm.  
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5. DISCUSSION 
5.1 Discussion of findings 
Adolescent sleep and prevalence of DSP  
Research has consistently shown sleepiness and delayed and irregular sleep patterns 
in adolescents, and it is likely that a large proportion of adolescents have a delayed 
sleep phase (DSP) with potentially severe negative consequences (Crowley et al., 
2007). In our sample of Norwegian high school students, 8.4 % reported DSP 
operationalized as difficulties falling asleep before 2 a.m. at least 3 nights per week 
together with much or very much difficulties waking up in the morning (paper 1). 
With less than 7 hours sleep duration on weekdays it appears that the students with 
DSP experience weekday sleep curtailment (Carskadon et al., 1980). In line with this, 
students with DSP frequently reported weekend rebound sleep. Maintaining delayed 
sleep times during weekends may have prevented these students from achieving a 
stable sleep phase advance, and it is possible that some of the students with DSP were 
“trapped” in a vicious cycle. This notion is supported by the fact that sleep onset 
latency on weekdays was long (more than 1 hour) in students with DSP despite the 
late bed times, possibly indicating an internal delay of the endogenous rhythm. 
Moreover, almost 80% of students with DSP reported problems advancing the sleep 
period. We note, however, that also students without DSP reported short weekday 
sleep duration (less than 8 hours during weekdays) and weekend rebound sleep. 
Hence, it appears that also students without DSP developed a sleep debt during 
weekdays. As such, paper 1 confirms previous reports of delayed and irregular sleep 
habits in adolescents. 
Correlates of DSP 
DSP was associated with lower school grades, more smoking, more alcohol use and 
higher scores on anxiety and depression (paper 1). Previous studies have shown that 
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students with better school grades report longer and more regular sleep on school 
nights and less sleep schedule delay during weekends than students with lower grades, 
and that students with adequate sleep perform better at school than students with less 
than adequate sleep (Wolfson and Carskadon, 1998; Wolfson and Carskadon, 2003; 
Dewald et al., 2010). Short sleep in adolescents has also been linked to elevated 
scores on anxiety and depression (Wolfson and Carskadon, 1998; Pasch et al., 2010; 
Regestein et al., 2010) and to the use of cigarettes, alcohol and illicit drugs (Pasch et 
al., 2010). The results from paper 1 are as such in agreement with previous findings 
of negative associations of delayed and irregular sleep patterns.  
 Due to the cross sectional design, the study does not yield information of the 
causal relationship between sleep and the outcome variables. It is, however, plausible 
to assume that the associations found in the present study may be related to the 
observed weekday sleep curtailment. Students who get more sleep may be more alert 
during the day and thus able to achieve better grades. In studies where school start 
times have been delayed, adolescents sleep longer on school nights, report less 
daytime sleepiness, obtain better grades and experience less mood disturbances 
(Wolfson and Carskadon, 2003; Owens et al., 2010; Vedaa et al., 2012). 
 The associations reported in paper 1 may also be explained in terms of diurnal 
preference. The adolescent sleep phase delay is associated with increased evening 
preference (Carskadon et al., 1993), and although chronotype was not assessed in the 
present study, students with DSP were likely high scorers on eveningness. Evening- 
and morning types have different optimal time windows for cognitive performance, as 
reviewed by Cavallera et al. (2011), and accordingly the relationship between DSP 
and academic performance may be attributed to circadian variations affecting 
performance in ways not mediated through sleep debt (Carrier and Monk, 2000). 
Several studies have linked eveningness to personality features such as neuroticism 
and conscientiousness, in particular low self-control (Digdon and Howell, 2008; 
Tonetti et al., 2009). Sensation seeking, impulsivity and low self-control may explain 
some of the problems associated with eveningness in terms of smoking and alcohol 
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use (Tonetti et al., 2010; Negriff et al., 2011; Prat and Adan, 2011; Urban et al., 
2011). Depression seems to be associated with an evening preference, independent of 
sleep-wake conditions (Hidalgo et al., 2009; Kitamura et al., 2010; Randler, 2011).  
 It is, however, likely that the negative associations of DSP are of a more 
complex and multi-directional nature. Whereas insomnia is a common symptom of 
depression, poor sleep has at the same time been shown to affect mood (Riemann, 
2007). Smoking is known to affect sleep architecture (Zhang et al., 2006) and may 
cause problems initiating sleep (Soldatos et al., 1980). At the same time, delayed 
sleep onset may provide an increased opportunity for smoking during late evening 
hours (Negriff et al., 2011). Similarly, alcohol usage may cause adolescents to stay 
awake late, leading to a delay in the sleep/wake rhythm. On the other hand, late bed 
times may endorse engagement in social evening events where alcohol is involved. As 
an example of more complex associations, findings by Singleton and Wolfson (2009) 
indicated that the effect of alcohol on sleep quality may lead to reduced academic 
performance.  
Prevalence of DSPD 
DSPD has been described as the most common circadian rhythm disorder (Dagan and 
Eisenstein, 1999; Lack and Wright, 2007). Still, prevalence rates in adult populations 
appear to be low and little is known about its prevalence in adolescents and young 
adults (Gradisar et al., 2011b). Survey studies have yielded prevalence rates of 
collections of symptoms resembling the disorder in adolescents and young adults, but 
results have not been univocal. Discrepancies are likely due to the use of different 
criteria to identify DSPD-like symptoms. In one end Lack (1986) reported that 17% of 
his student sample matched the criteria for at least a mild form of DSPD, whereas in 
the other end Hazama et al. (2008) estimated the prevalence of “probable DSPD” to 
0.48% in their sample of Japanese students. In view of these discrepancies, results 
from paper 1, although not addressing DSPD directly, may add importantly to the 
field. In our sample, 5.7% reported DSP in addition to daytime consequences and 
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problems advancing the sleep phase, symptoms representing the essential features of 
DSPD (American Academy of Sleep Medicine, 2005).  
Sleep in DSPD  
Polysomnographic data presented in paper 2 revealed that the major differences 
between patients with DSPD and healthy controls in terms of sleep were related to 
timing, whereas sleep duration and sleep stage distribution were essentially similar in 
the two groups. These findings support the statement in the ICSD-2 that sleep in 
DSPD is normal when patients are allowed to sleep on a self-preferred schedule 
(American Academy of Sleep Medicine, 2005), but contrast findings in the only 
previous controlled polysomnography study performed on patients with DSPD, where 
sleep quality was found to be reduced in the patient group (Watanabe et al., 2003). In 
our study participants were allowed to go to bed at a self-chosen time, whereas a 
habitual sleep time protocol (which possibly may reflect influences of external 
factors) was used by Watanabe et al. (2003). Hence, slight methodological 
dissimilarities can account for some of these inconsistencies. 
 Interestingly, despite the fact that participants in our study were allowed to 
sleep on a self-chosen schedule, SOL was slightly prolonged in the DSPD group. It is 
possible that patients with DSPD had earlier habitual bed times with respect to their 
endogenous circadian phase, which might have influenced bed time decision also 
upon instructions of a self-chosen sleep schedule. Moreover, the sleep onset process 
in patients with DSPD may be more vulnerable to external disturbances (i.e. the PSG 
montage) than healthy controls. Lack and Wright (2007) have proposed that patients 
with DSPD may develop conditioned sleep onset insomnia based on previous 
experiences of not being able to fall asleep. In such case, future treatment protocols 
should incorporate elements to address this issue, e.g. stimulus control. In a study by 
Gradisar et al. (2011a), bright light therapy was used in combination with cognitive 
behavioural therapy, addressing amongst others the associated insomnia. However, 
findings by MacMahon et al. (2006) give no indication of attention bias for sleep 
related stimuli (which is common in primary insomnia) in patients with DSPD.  
57
Circadian phase and phase angle relationship in DSPD 
In line with previous findings (Shibui et al., 1999; Wyatt et al., 2006; Chang et al., 
2009), DLMO was delayed in participants with DSPD (paper 2). Moreover, similar to 
what was reported by Wyatt et al. (2006) and Chang et al. (2009), no difference in 
phase angle relationship was observed between the groups. Prolonged phase angle 
relationship has, however, been reported in other studies of patients with DSPD 
(Ozaki et al., 1996; Uchiyama et al., 2000a; Watanabe et al., 2003). Hence, the issue 
of a possible disassociation between circadian phase and sleep timing in DSPD is 
unresolved. Discrepancies in findings may in part be explained by the impact of 
external constraints, as suggested by Mongrain et al. (2004). It is also possible that 
DSPD may arise from different pathophysiological mechanisms, e.g. phase angle may 
be prolonged in patients where the delayed sleep phase is related to abnormalities in 
homeostatic processes (Uchiyama et al., 2000b) but not in patients with particularly 
long Ĳ (Czeisler et al., 1981). This, however, remains speculations and larger scaled 
studies are needed in order to elucidate this issue.  
 Taken together, results from paper 2 support the argumentation by Chang et al.
(2009) that when allowed to sleep on a schedule free from social restraints, sleep in 
DSPD takes place at a normal phase angle allowing normal sleep quality.  
Short-term treatment of DSPD with bright light and melatonin  
Most current treatment approaches for DSPD aim to correct the sleep phase delay by 
means of bright light and/or melatonin. However, no consensus exists with respect to 
timing, dosage, duration and adjunct behavioural instructions. Placebo controlled 
treatment studies are scarce both in terms of bright light (Rosenthal et al., 1990; Cole
et al., 2002; Lack et al., 2007; Gradisar et al., 2011a) and melatonin (Dahlitz et al., 
1991; Nagtegaal et al., 1998b; Kayumov et al., 2001; Mundey et al., 2005; Rahman et 
al., 2010a), in particular in adolescents and young adults (Gradisar et al., 2011a). In 
paper 3 we reported that two weeks of treatment involving administration of bright 
light and exogenous melatonin alongside gradual advancement of rise time in a four-
armed, randomized, placebo controlled design, produced a phase advance irrespective 
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of treatment condition. Hence, no differences were found between the placebo group 
and the treatment groups, and no additive effects of bright light and melatonin could 
be observed, contrasting previous findings in healthy persons (Burgess et al., 2003; 
Wirz-Justice et al., 2004; Revell et al., 2006).The finding that a similar phase 
advance was produced in the placebo group who was instructed to gradually advance 
rise time was unexpected. It is known that the timing of the sleep period itself may act 
as a zeitgeber, but its influence on the circadian phase is believed to be weak (Duffy
et al., 1996; Danilenko et al., 2003). Still, some previous studies have suggested that 
sleep timing may be advanced in patients with DSPD through behavioural 
instructions, at least in less severe cases (Cole et al., 2002; Sharkey et al., 2011). 
Findings in paper 3 indicate that gradual advancement of rise time schedules may 
effectively produce a phase advance also in more severe cases of delayed sleep phase. 
In our study, sleep duration was reduced across groups, likely due to the imposed rise 
time advancement. Advanced rise times may contribute to a sleep phase advance 
through homeostatic processes by inducing a sleep debt which in turn instigates 
earlier sleep onset (Borbely, 1982). The early rise times may also have promoted 
exposure to outdoor light during the optimal phase advancing portion of the PRC also 
in the dim light conditions. In addition, the possibility of a phase advancing effect of 
the 300 lux dim light cannot be ruled out. Hence, phase advancement may be 
attributed to light also in the placebo light groups. In the present study, sleep diary 
scores on sleep quality improved across the groups and taken together with reduced 
scores on the PSQI and the BIS it appears that short-term effects of the present 
treatment protocol were beneficial, also in the face of reduced sleep duration.
Long-term treatment of DSPD with bright light and melatonin  
Several clinical reports indicate that the effect of light and melatonin fades out upon 
termination of treatment (Alvarez et al., 1992; Dagan et al., 1998b; van Maanen et al., 
2011). Accordingly, treatment protocols should address the sleep phase delay in a 
two-step manner by 1) achieving and 2) maintaining a phase advance. However, few 
controlled trials have reported long-term treatment effects of DSPD. In paper 3 we 
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reported that three months of treatment with bright light and melatonin in an open 
label follow-up study allowed the patients to maintain the advanced sleep phase 
achieved during the two-week intervention. Hence, there was a continued 
effectiveness of bright light and melatonin over three months with no signs of 
tolerance development or adverse outcomes. At three-month assessment sleep 
duration had increased to baseline levels, indicating that although gradual 
advancement of rise time induces a sleep phase advance at the cost of sleep duration 
in the initial phase, normal sleep duration is resumed when treatment is maintained 
over sustained periods of time. Since sleep duration relies on the timing of the sleep 
period in relation to the endogenous circadian phase (Borbely, 1982; Dijk and 
Czeisler, 1995) the resumption of normal sleep duration can be taken as support for a 
well-adapted sleep schedule/circadian phase relationship. At three-month follow-up, 
the PSQI and the BIS scores were reduced in the treatment group, not only with 
respect to the baseline levels but also with respect to the two-week assessment, 
indicating that the beneficial treatment effect increased as the sleep 
schedule/circadian phase stabilised. In contrast, patients not receiving treatment 
relapsed into delayed sleep times despite the fact that participants had become 
familiar with the principles of the gradual rise time advancement and maintenance 
protocol. Accordingly, although behavioural interventions in the form of rise time 
schedules appear capable of producing a sleep phase advance in patients with DSPD, 
information and training related to these concepts do not appear to suffice for 
sustained effects. Motivational issues may have strong impact on compliance to the 
treatment regime since it involves structuring the daily schedule, in particular in 
young patients with DSPD. It is possible that motivational therapy, such as 
Motivational Interviewing, can increase adherence to the advanced sleep schedules. In 
the study by Gradisar et al. (2011a) an advanced sleep schedule was more or less 
maintained for six months in adolescents with DSPD after the initial sleep phase 
advance. 
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5.2 Methodological considerations 
5.2.1 Study design 
Study 1 
Study 1 was an internet-based, cross sectional survey. A cross sectional design allows 
for large sample sizes, and is therefore well suited to calculate prevalence rates. In the 
present study, data were collected in a large and representative sample of Norwegian 
high school students with a relatively high response rate of 69.8%. Still, results must 
be interpreted with caution since we have no information about the non-responders 
(30%) and potential selection bias. Using a cross sectional design it is also possible to 
address associations between variables such as risk factors for the outcome of interest. 
It is, however, important to note that cross sectional studies yield information only 
with respect to a given time, hence no conclusions can be drawn concerning cause 
and effect relationships. In order to determine prognoses or outcome, large studies of 
longitudinal designs (participants followed up over time) are required. All data in the 
present study were self-reported, and relationship between constructs may therefore 
be influenced by the common method bias.  
Study 2 
Study 2 comprised both a case control study and a randomized, placebo controlled 
clinical trial (RCT) with a randomized, controlled open label follow-up study. The 
sample included a group of 40 patients with DSPD and 21 healthy controls in the age 
range 16-25 years. Mean age did not differ between the groups. Most participants 
were students attending high school, college or university. High school students more 
often have early hour obligations than college and university students, but since the 
proportion of students from each institution was similar in the different groups any 
major effect on the outcome of the study is unlikely. The study was conducted in 
Bergen, Norway, at 60.39°N, yielding large differences in solar day length between 
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midsummer and midwinter. In the present study, we did not systematically account for 
effects of season which potentially may have affected the trial outcome. However, the 
project ran for almost 4 years with continuous enrolment across seasons, with no 
obvious difference between the groups with respect to season of enrolment. 
Participants in the DSPD group had volunteered to participate in a treatment study, 
causing a potential selection bias towards help-seeking patients. Participants in the 
control group, however, received only a small compensatory fee. Hence, there is a 
potential selection bias in this group towards resourceful and socially engaged 
youngsters. 
 In the case control study, polysomnographic measures of sleep were compared 
between 35 patients with DSPD and 19 controls (paper 2). For the remaining 
participants (5 DSPD, 2 controls), PSG recordings from night 2 were either missing 
due to technical issues (5 participants) or considered not valid due to non-compliance 
with respect to the protocol (i.e. forced early awakening, 2 participants). The missing 
PSG data were thus not expected to represent a selection bias. Case control designs 
are well suited to address characteristics of a patient group with respect to healthy 
individuals. To reduce the impact of confounding factors, we carefully sought that 
participants in both groups followed the exact same study protocol. In particular, the 
impact of external influence on the sleep schedule prior to and during PSG recording 
was reduced by instructing the participants to sleep on a self-chosen sleep schedule. 
Still, in case control designs it is impossible to adequately account for all potential 
confounding factors and apparent relationships may thus not be causal. The four-
armed clinical trial was randomized and double blinded. Since randomization and 
blinding reduce potential bias, such trials are considered to yield reliable measures of 
intervention effects. The two-armed follow-up study was not blinded or placebo 
controlled, hence differences between groups may be explained in terms of 
expectation bias. Few participants dropped out from the trial during treatment (Fig.3) 
and analyses were carried out according to intention to treat, hence reducing potential 
bias. 
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5.2.2 Procedures 
Operationalization of DSP 
In paper 1, DSP was operationalized as problems falling asleep before 2 a.m. at least 
3 nights per week together with much/very much difficulties waking up in the 
morning. These criteria were based on descriptions in the first edition of the 
international classification of sleep disorders (ICSD-1) (American Academy of Sleep 
Medicine, 1990) that patients with DSPD typically complain primarily of chronic 
difficulty in falling asleep before 2 a.m. or difficulty awakening at the desired or 
necessary time in the morning to fulfil social or occupational obligations. Using 
criteria related to descriptions of DSPD we aimed to identify students with a severe 
and potentially debilitating delayed sleep phase. The prevalence rate of DSPD was not 
addressed in the study. We report, however, the prevalence of students with DSP 
together with related daytime consequences and problems advancing the sleep/wake 
cycle, which may indicate at least a mild form of DSPD. No sleep diary was included 
to show a stable, delayed sleep pattern, and students were not screened for other 
potential disorders. Accordingly, no DSPD diagnoses could be made, and the 
practical value of the prevalence rate obtained may thus be questioned.  
Screening and diagnostic criteria 
In study 2, patients with DSPD were diagnosed according to the criteria of the ICSD-
2 (American Academy of Sleep Medicine, 2005), confirmed by one week of sleep 
diary. In diagnosing DSPD there are no requirements with respect to clock times. 
Patients should experience a phase delay in relation to the desired rhythms. However, 
in order to ensure that the DSPD group and the control group did not overlap with 
respect to sleep timing, we included only patients with DSPD with sleep onset later 
than 2 a.m. at least 3 days per week and controls with sleep onset before midnight at 
least 3 days per week, later than 2 a.m. no more than 2 days per week and sleep onset 
latency >30 min <3 days per week. All participants were thoroughly screened for 
other medical or psychiatric disorders, and PSG was used to screen for sleep apnea 
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and periodic limb movement disorder. Thus, our sample consisted of otherwise 
healthy young people with DSPD and healthy young people with normal sleep 
schedules. 
Sleep assessment 
In paper 2 we compared polysomnographic measures of sleep between patients with 
DSPD and controls. The self-chosen sleep schedule protocol allowed participants to 
sleep until spontaneous awakening for 3 days prior to the PSG night used for data 
analyses and 4 days prior to saliva sampling (see Fig.3), hence ruling out effects of 
chronic sleep debt or enforced asynchrony. Although the results are in line with 
descriptions of DSPD in the ICSD-2 (American Academy of Sleep Medicine, 2005), 
they contrast findings in the only previous controlled polysomnographic study 
performed on patients with DSPD (Watanabe et al., 2003). It is likely that slight 
differences in protocols may be the cause of these discrepancies. In the habitual sleep 
times protocol used by Watanabe et al. (2003), it appears that patients were instructed 
to go to bed at their usual bed time. Usual bed times may be affected by external 
factors such as work, school or input from parents and partners, and the long phase 
angle may thus reflect an influence of external restraints on habitual sleep time rather 
than underlying pathophysiology. Moreover, the control group in that study slept at a 
fixed time (23 p.m. – 7 a.m.), whereas both groups in our study received instructions 
of a self-chosen bed time.  
 In paper 3, sleep was assessed by means of sleep diary and actigraphy 
recordings. Prior to intervention, sleep was assessed on a habitual sleep schedule. At 
two-week assessment (the last intervention week) sleep was assessed on a gradual 
advancement (and subsequent maintenance) of rise time schedule. At three-month 
assessment (the last intervention week), sleep was assessed on a habitual sleep 
schedule or a gradual advancement of rise time schedule in the no-treatment and 
treatment groups, respectively. Seven day average (5 weekdays and 2 weekend days) 
was used for analyses. In terms of sleep diary, items missing on a weekday were 
replaced by the average of the remaining weekdays (27 days at baseline, 6 days at 
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two-week assessment, 2 days at three-month assessment were replaced), whenever an 
item was missing on a weekend day it was replaced by the other weekend day (3 days 
at baseline, 0 days at two-week assessment, 1 day at three-month assessment were 
replaced). 
Assessment of circadian phase 
By measuring melatonin in saliva sampled at hourly intervals during the period of 
assumed DLMO, we were able to perform at home based assessment of circadian 
phase (Pandi-Perumal et al., 2007). Saliva was sampled from 7 p.m. to self-chosen 
bed time to allow assessment of circadian phase without restricting sleep. However, in 
several cases DLMO could not be calculated due to consistent low melatonin levels in 
all samples. In paper 2, DLMO could be calculated in 20 participants in the DSPD 
group and 8 controls. In paper 3, DLMO could be calculated at both baseline- and 
two-week assessment in 16 participants. Saliva samples were also collected at three-
month assessment, but DLMO could be calculated at both baseline- and three-month 
assessment in only 5 participants, which were considered too low for analyses. 
Consequently, DLMO is reported only for baseline and two-week assessment. It is 
possible that by allowing a self-chosen bed time, some participants went to bed earlier 
than usual and therefore before DLMO. Participants were scheduled for rise time at 7 
a.m. on the following morning, which may have augmented the tendency to go early 
to bed. Also, the sunglasses worn by the participants were very dark and probably 
limited the number of activities participants could engage in. In participants where no 
rise in melatonin concentration was observed, the time for collection of the last saliva 
sample was more than 2 hours earlier than their bed time on the previous night (PSG 
night) compared to less than an hour in participants where DLMO could be 
calculated, indeed indicating that several participants went to bed earlier than usual. It 
is, however, also possible that behavioural factors temporarily suppressed evening 
melatonin. Since sampling was at-home based it was not possible to confirm that all 
instructions were followed. Inconsistent use of the sunglasses may have caused light 
exposure and thus led to a suppression of melatonin. The participants received no 
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specific instructions regarding posture or physical activity and occasional use of non-
steroidal anti-inflammatory drugs was not prohibited. Both non-steroidal anti-
inflammatory drugs and physical activity may suppress melatonin secretion. Saliva 
samples collected at 7 and 8 a.m. on the morning after DLMO assessment showed 
increased melatonin levels in all but two participants (data not included in the theses), 
hence arguing against the possibility that participants were low melatonin secretors 
(Rahman et al., 2010b). In estimating phase angle relationship, PSG was obtained on 
the night prior to DLMO sampling (night 4 and 5, respectively). Hence, there was no 
direct temporal relationship between DLMO and sleep onset/offset parameters. It is, 
however, not likely that DLMO changes much over such a short time interval (one 
day), considering the findings by Wyatt et al. (2006) of temporal stability of DLMO. 
Randomization, placebo and blinding procedures 
Upon enrolment in the clinical trial, participants were chronologically allocated to the 
respective treatment conditions according to randomization lists. The four-armed 
clinical trial was double blinded, preventing allocation bias. In contrast, the two-
armed follow-up study was not blinded, and strict adherence to the lists was required 
to avoid allocation bias. Adherence to the lists was ensured by the internal trial 
monitoring procedures. 
 In the clinical trial we faced a challenge with respect to the placebo light 
condition since it involved exposure of 300 lux intensity light at an optimal circadian 
phase. Dim light has been shown to have significant impact on the circadian rhythm 
(Boivin et al., 1996; Zeitzer et al., 2000), dependent on the duration of exposure and 
background illumination. Furthermore, although participants were blinded with 
respect to light intensity and the expected effects, it is likely that some participants 
realized that the red light represented the placebo condition (this was not assessed in 
the study). Hence, participants may not have been blinded with respect to the light 
condition. Conducting the study, there was also a risk that participants would reveal 
the colour of their lamp to the study personnel. However, no such events were 
reported to take place, likely due to the emphasis put on this issue when instructing 
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the participants. In the case control study, PSG scoring was performed blind with 
respect to the group identity of the participants. However, clock times were not 
concealed and group identity often obvious from late bed- and rise times. 
Treatment protocol 
In the clinical trial, timing for light/capsule administration was based on times for 
spontaneous awakening on the first day of treatment, which is assumed to be 
approximately 2 hours after CTmin (Bjorvatn and Pallesen, 2009). This aspect of the 
treatment protocol was essential, since we aimed to investigate a treatment protocol 
suitable for use in primary health care. However, by not estimating CTmin or DLMO 
prior to treatment, there was a risk of initiating treatment at a phase delaying portion 
of the PRC. Moreover, the protocol used in the present study was based on the 
assumption that patients were able to advance the circadian phase at least 1 hour per 
day. It is possible that some participants may have achieved smaller phase advances 
and, consequently, had scheduled rise times prior to CTmin on subsequent days. 
Although sleep timing and DLMO were advanced in all treatment conditions, we 
cannot rule out the possibility that some participants on occasions were exposed to 
bright light prior to CTmin which may produce a phase delay, counteracting the phase 
advance achieved by bright light after CTmin and possibly explaining the lack of 
difference between the bright light and dim light groups. In clinical practice, this 
pitfall may be avoided by tailoring treatment to the individual patient, for example by 
advancing rise time by only 30 minutes each day. The risk of administering melatonin 
at a phase delaying time was lower. However, research has shown that different doses 
of melatonin have different time windows for optimal effects (Burgess et al., 2010). It 
is possible that melatonin administered at late times wash over to the phase delaying 
part of the curve, counteracting the phase advancing effect of melatonin at the phase 
advancing part of the curve. Accordingly, we cannot rule out the possibility that 
treatment with bright light and/or melatonin at more optimal times or doses may 
produce larger treatment effects than what is reported in paper 3. Treatment in the 
present study was based on administration of full spectrum light of 10 000 lux 
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intensity and 3 mg exogenous melatonin, and results may not be directly transferable 
to different doses of melatonin and/or light of different 
wavelengths/intensities/durations.  
 During the two-week intervention, compliance to treatment was high in all 
groups whereas compliance was somewhat lower during the three month intervention 
(data not included in the thesis). No serous or long lasting adverse events were 
reported in the trial. During the two-week intervention, mild possible side effects such 
as eye itch, and headaches were reported by approximately one third of the 
participants, with no differences between the treatment conditions. During the three-
month intervention one sixth reported such side effects.  
5.2.3 Instrument validity  
Sleep assessment 
Yielding objective information about both quality and quantity of sleep, PSG 
represents the gold standard for measuring sleep (Rechtschaffen and Kales, 1968; Iber
et al., 2007; Carskadon and Dement, 2011). In study 2, PSG was performed 
ambulatory following an adaptation night, minimizing potential first night effects of 
the procedure on sleep (Agnew et al., 1966). Still, PSG is invasive and may influence 
sleep duration and quality. Despite the fact that PSG is regarded the classical 
objective measure of sleep, with standardized criteria for sleep stage assignment (Iber
et al., 2007), the scoring of PSG protocols is highly subjective and rather large inter- 
and intra-rater variability have been described (Stepnowsky et al., 2004). In the 
present study, all PSG protocols were scored by a single, experienced, registered 
polysomnographic technologist (RPSGT), hence increasing the reliability of the 
results. 
 PSG is invasive and costly and yields information about one night of sleep 
rather than habitual sleep pattern. Since DSPD seems to reflect a sleep phase 
misalignment rather than abnormal sleep, sleep and treatment effects are likely better 
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described by less invasive procedures used over longer periods of time. This is also 
acknowledged in the ICSD-2 (American Academy of Sleep Medicine, 2005) where 
sleep diary or actigraphy rather than PSG is required for diagnosing DSPD. In the 
clinical trial, objective and subjective measures of sleep were therefore assessed by 
means of actigraphy and sleep diary. Although the objectivity of actigraphy 
recordings may be questioned, sleep diary and actigrapy are complimentary may be 
considered the recommended measurements in this kind of sleep research (Ancoli-
Israel et al., 2003; Morgenthaler et al., 2007)  
Assessment of circadian phase and phase angle relationship 
DLMO is considered a robust marker of circadian phase, and at-home based DLMO 
assessment appears to correlate well with laboratory assessment in most patients 
(Pullman et al., 2012). However, in some cases, at home sampling deviates from 
laboratory samples likely due to differences in behaviour or environment (Pullman et 
al., 2012). Although participants in study 2 received thorough instructions with 
respect to the saliva sampling procedure, we cannot confirm that all instructions were 
followed. The saliva samples were analysed using an enzyme-linked immunosorbent 
assay (ELISA) with high sensitivity in concentration ranges around the DLMO 
threshold which was set to 4 pg/ml (Nagtegaal et al., 1998a). Samples were analysed 
in duplicates by spectrophotometry. Samples from each participant at one assessment 
point were analysed with the same kit. Intra-assay variance was kept low, and in cases 
of discrepancies between duplicates a third analysis was performed. DLMO estimates 
by ELISA technique have been validated as an accurate tool in patients with DSPD 
(Rahman et al., 2009), hence we consider the output from analyses to be reliable. In 
estimating DLMO, scheduled times for sampling (7 p.m., 8 p.m. etc) were used since 
few participants reported the accurate sampling times. Since it is not possible to 
confirm that participants adhered to the scheduled sampling times, inaccuracies in 
sampling times may have influenced the results.  
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Questionnaires 
All questionnaires used in the study (the AUDIT, the HADS, the PSQI and the BIS) 
are commonly used and of high validity (Buysse et al., 1989; Bjelland et al., 2002; 
Reinert and Allen, 2007; Pallesen et al., 2008). They are, however, in nature based on 
self-report and designed to screen for collections of symptoms. Hence clinical status 
with respect to alcohol abuse, anxiety, depression and sleep problems cannot be 
confirmed.  
5.2.4 Statistical analyses 
Sample size and statistical power  
Data reported in paper 1 were collected in a large and representative sample of 
Norwegian high school students with a relatively high response rate. The case control 
study reported in paper 2 is, to our knowledge, the largest controlled study assessing 
objective measures of sleep in patients with DSPD. It is, however, worth mentioning 
that rather large descriptive differences on several parameters reported in paper 2 (e.g. 
TST and phase angle) may have failed to reach statistical significance due to large 
inter-individual differences in the present study (high variance). It is possible that 
DSPD may arise from different pathophysiological sources, and that larger scaled 
studies may be needed to detect and to differentiate between them. Results from the 
clinical trial reported in paper 3 were based on 40 patients with DSPD. Pre-
calculations indicated 60 participants to be enrolled for adequate statistical power in 
the four-armed intervention. However, this was not possible due to recruitment 
challenges. Hence, a potential limitation of the clinical trial was reflected by the small 
group sizes, which may account for the fact that no differences were observed 
between the treatment conditions. The rather smaller sample in which DLMO could 
be calculated is a particular limitation to the study. In paper 2 and 3, group differences 
were reported in terms of statistical significance as well as effect size calculations. 
Effect size yields information about the size of the difference observed between 
groups/sessions, hence it extends to the clinical interpretation of the findings. 
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Intention to treat 
Analysing the results from the clinical trial (paper 3), values were moved forward 
from baseline in cases of drop outs and missing data (intention to treat). Intention to 
treat is a conservative approach commonly used in trials to reduce bias, and provides 
an estimate of treatment effectiveness. Of the 40 participants enrolled in the clinical 
trial, two participants dropped out during the two-week intervention (one from the 
bright light condition, one from the melatonin condition) whereas three participants 
withdrew from the study during the three-month follow-up period (2 from the no-
treatment condition, 1 from the treatment condition) (see Fig.3). In addition, sleep 
diaries at two-week assessment were missing from 2 participants in the placebo group 
and 1 in the bright light group, actigraphy was missing from 1 in the placebo group, 
PSQI was missing from 2 in the placebo group, 2 in the bright light group and 1 in the 
melatonin group, and BIS and HADS were missing from 1 participant in the 
melatonin group. At three-month assessment, sleep diary was missing from 1 
participant in the no-treatment group. PSQI was missing from 1 in the no-treatment 
group and from 1 in the treatment group. Analyses where missing data post-treatment 
were excluded from the data set yielded similar results as the intention to treat 
analyses (data not presented in the theses). Due to the smaller sample size, intention to 
treat was not used in DLMO analyses.  
5.2.5 Ethics 
The studies in this theses were conducted in accordance with the Helsinki declaration 
and approved by adequate instances. In study 1, participants and their parents had 
received written information about the study prior to participation. A passive consent 
procedure was applied, which was considered appropriate since data were collected 
anonymously. In study 2, participants (and parents when participants were < 18 years) 
received written and oral information about the study and gave both written and oral 
consent. All participants in study 2 received a compensation fee proportional to the 
time invested. The clinical trial was conducted in accordance with good clinical 
practice (GCP) of which the PhD students conducting the trial were certified, and 
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internal monitoring procedures were incorporated in the design. Since no guidelines 
exist with respect to treatment of DSPD and adequate treatment is often not provided 
these patients, participants in the three-month no-treatment group were not offered 
treatment after follow up. During the two-week intervention, also participants in the 
placebo group received behavioural instructions which could potentially benefit the 
sleep phase through altered sleep practices (Brown et al., 2002).  
5.3 Implications and future perspectives 
The overarching goal of this theses was to contribute to increased understanding and 
ultimately to better clinical management of patients with DSPD. In paper 1 we 
estimated a prevalence of DSP together with problems advancing the sleep phase and 
at least one daytime consequence of 5.7% in our sample of Norwegian high school 
students. Although it is important to clarify the true prevalence of DSPD in 
adolescents and young adults, also severe DSP is associated with a wide range of 
negative outcomes. Statistics Norway reports that a total of 324 990 adolescents 
between 15 and 19 years were living in Norway at January 1st 2012. Accordingly, 
more than 16 000 adolescents in Norway may have a debilitating delayed sleep phase. 
It is essential that effective strategies to prevent and overcome a delayed sleep phase 
are communicated to adolescents, parents and teachers. As shown by Brown et al.
(2002), increased knowledge of sleep hygiene has beneficial effects on sleep practices 
and leads to improved sleep quality, and fixed advanced sleep times have been shown 
to phase advance the circadian rhythm in patients with subclinical DSPD (Sharkey et 
al., 2011). Later school start times may allow adolescents to sleep at more optimal 
times according to their internal circadian rhythms, and appear to increase weekday 
sleep duration rather than bring about further sleep phase delay (Epstein et al., 1998; 
Owens et al., 2010; Vedaa et al., 2012).  
 In some adolescents and young adults, however, attempts to advance the sleep 
phase and adhere to societal norms are unsuccessful. The reason why some develop 
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DSPD is not known, although mechanisms related to circadian and homeostatic 
abnormalities as well as behavioural factors and factors related to innate traits (i.e. 
personality factors) have been proposed. In paper 2 we show delayed sleep and 
delayed circadian phase in patients with DSPD, with no indication of homeostatic 
dysregulation in terms of prolonged phase angle or altered sleep architecture. Hence, 
although the cause of circadian misalignment in terms of Ĳ, light sensitivity and 
contributing behavioural factors needs to be further addressed in the future, results 
from the present study support the idea that DSPD treatment protocols should aim to 
advance the internal circadian phase. 
 In specialised sleep clinics, DSPD is often treated with bright light and/or 
melatonin. However, no guidelines for treatment exist and management of DSPD in 
primary health care is often poor. Considering the presumably large number of 
adolescents with DSPD, it seems crucial that treatment protocols suitable for use in 
primary health care are established. In paper 3 we demonstrated an effect of a DSPD 
treatment protocol in which the timing for bright light/melatonin administration was 
based on behaviour rather than pre-treatment measurements of DLMO or CTmin. The 
results indicate that an initial phase advance may be achieved through gradual 
advancement of rise time. The protocol is simple and can be used by anyone with 
knowledge about circadian rhythms and sleep regulation, and treatment can be 
successfully initiated even when no specialized equipment or facilities are available. 
Hence, results from the present study may be directly transferable to clinical practice. 
In the maintenance phase of DSPD treatment, the use of bright light/melatonin may be 
necessary to prevent relapse. In the present study, no sign of tolerance development 
was observed when light and melatonin were used over a period of 3 months with no 
reports of serious or long lasting adverse events. It therefore seems that adolescents 
and young adults with DSPD may be able to adhere to work/school schedules over 
time through sustained use of bright light/melatonin. Results from paper 3 provide a 
platform clinical management, but also bring forward new research questions. 
According to current chronobiological knowledge, bright light is the most potent 
zeitgeber in humans, and the finding that an equal phase advance was produced in the 
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placebo group calls for further investigations as of the contributions of dim light 
exposure and sleep schedules. Also the effect of a phase advance on daytime 
functioning and sleepiness in patients with DSPD needs to be explored. Objective and 
subjective measures of sleepiness as well as measures of cognitive functioning were 
included in study 2, and will be analysed and published in the near future.  
5.4 Conclusion 
In paper 1 we reported a prevalence of DSP operationalized as problems falling 
asleep before 2 a.m. at least 3 nights per week together with much/very much 
difficulties waking up in the morning of 8.4 %. DSP was associated with lower school 
grades, more smoking, more alcohol use and higher scores on anxiety and depression. 
In paper 2 we reported delayed timing of sleep and DLMO in patients with DSPD. 
The sleep period occurred, however, at a normal phase angle and once sleep was 
initiated, no differences in sleep parameters were observed between patients with 
DSPD and controls. In paper 3 we reported a phase advance with respect to sleep 
timing and DLMO after short-term treatment involving gradual advancement of rise 
time, with no additional effect of administration of bright light and/or melatonin. 
Long-term treatment with bright light and melatonin allowed maintenance of the sleep 
rhythm whereas termination of treatment caused relapse into delayed sleep times.  
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